<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intrauterine contraception: Management of side effects and complications</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intrauterine contraception: Management of side effects and complications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Intrauterine contraception: Management of side effects and complications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katherine D Pocius, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah A Bartz, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Courtney A Schreiber, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2152165134"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Intrauterine contraception is highly effective, very safe, and generally well tolerated by most people. As such, it has become an increasingly popular method of contraception. Despite the overall excellent safety profile, side effects and complications can occur at the time of insertion and at different time points following insertion.</p><p>This topic will address diagnosis and management of side effects and complications related to intrauterine contraception in a temporal fashion broken down by typical onset of presentation in relation to timing from intrauterine device (IUD) insertion. Issues related to intrauterine contraception types, patient candidates and device selection, as well as the noncomplicated insertion and removal procedure, are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">"Intrauterine contraception: Candidates and device selection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3267.html" rel="external">"Intrauterine contraception: Insertion and removal"</a>.)</p><p></p><p>In this topic, the terms "woman/en" or "patient(s)" may be used as described in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender-expansive individuals.</p><p class="headingAnchor" id="H1804189442"><span class="h1">IUD NOMENCLATURE</span><span class="headingEndMark"> — </span>Alternate terms for intrauterine contraception include the intrauterine device (IUD), intrauterine contraceptive (IUC), or intrauterine system (IUS, used in reference to the progestin-containing devices). In this topic, we use the term IUD for all types of intrauterine contraception [<a href="#rid1">1</a>]. A discussion of the various IUD types and selection is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types"</a> and  <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">"Intrauterine contraception: Candidates and device selection"</a>.)</p><p>For this topic, we will use the following abbreviations:</p><p class="bulletIndent1"><span class="glyph">●</span>Copper 380 mm<sup>2</sup> IUD (US commercial name Paragard)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">Levonorgestrel</a> 52 mg IUD (US commercial names Mirena or Liletta): LNG 52 mg</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">Levonorgestrel</a> 19.5 mg IUD (US commercial name Kyleena): LNG 19.5 mg </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">Levonorgestrel</a> 13.5 mg IUD (US commercial name Skyla): LNG 13.5 mg </p><p></p><p>Other IUDs studied in international research are described where relevant below using IUD shape and dose.</p><p class="headingAnchor" id="H750402231"><span class="h1">PREVALENCE OF COMPLICATIONS</span><span class="headingEndMark"> — </span>Complications are rare and include expulsion (3 to 6 percent in the first year), pelvic inflammatory disease (PID) (1 percent in first 20 days, and 0.5 percent in first 3 to 6 months), contraceptive failure (0.1 to 0.6 percent in first year) with increased risk of ectopic pregnancy if failure does occur, and perforation (0.01 percent) [<a href="#rid2">2-10</a>]. Malposition is typically of less significance and occurs in up to 10 percent of patients. The common side effects of pain and irregular bleeding are the most frequently cited reasons for IUD removal within the first 6 months (28 to 35 percent and 10 to 19 percent, respectively) [<a href="#rid11">11</a>]. Thus, recognition and management of these concerns is important for improving patient satisfaction and continuation rates.</p><p class="headingAnchor" id="H3463829605"><span class="h1">RISK FACTORS FOR COMPLICATIONS</span><span class="headingEndMark"> — </span>Though IUDs can generally be safely used by most individuals, some populations may be at increased risk of complication. As sub-population patterns of IUD use change, recognition of risk factors for side effects and complications becomes increasingly important.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Young age</strong> – Young age, typically defined as age 25 years or less, has been associated with IUD failure (ie, pregnancy) and likely with IUD expulsion. Young age does not appear to increase risk of other IUD complications such as perforation or infection [<a href="#rid12">12</a>]. The mechanisms are not known.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IUD failure</strong> – Young age has been associated with a higher rate of IUD failure, presumably secondary to increased fertility within this age group. In a retrospective claim-based study including over 90,000 users who received either a copper or levonorgestrel-releasing IUD, people age 15 to 19 years were nearly 30 percent more likely to have an IUD failure compared with people age 20 to 24 years and 40 percent more likely to experience IUD failure compared with users age 25 to 44 years [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IUD expulsion</strong> – Although there is conflicting evidence, the majority of studies report that an age of 25 years or less is associated with increased risk of IUD expulsion [<a href="#rid14">14-16</a>]. In a systemic review evaluating IUD expulsion among users aged 25 years or younger compared with older IUD users, six studies suggested increased risk of expulsion with decreased age for the copper 380 mm<sup>2</sup> IUD. Results regarding expulsion risk with LNG IUD were mixed [<a href="#rid17">17</a>]. The risk of IUD expulsion may be particularly increased for very young individuals. In a planned secondary analysis of a prospective cohort study of over 5400 people who were provided with the IUD (copper or levonorgestrel-releasing) of choice at no cost, subjects age 14 to 19 years had more than twice the risk of IUD expulsion compared with subjects age 20 years and older, regardless of parity and IUD type, at up to 36 months of follow-up [<a href="#rid4">4</a>]. For comparison, during the first year after IUD insertion in nonpostpartum subjects of all ages, expulsion occurs following 3 to 10 percent of copper 380 mm<sup>2</sup> IUD insertions and 3 to 6 percent of <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">levonorgestrel IUD</a> insertions [<a href="#rid3">3,4,18-21</a>]. Of note, nulliparity, which is more common in younger individuals, does not appear to increase the risk of IUD expulsion [<a href="#rid3">3,4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum or postabortion</strong> – Risk of IUD expulsion is increased with both immediately and delayed postpartum IUD insertion and following later abortion [<a href="#rid22">22,23</a>]. There is no increased risk of expulsion with insertion after first-trimester abortion compared to interval insertion [<a href="#rid24">24</a>]. Risk of IUD perforation is slightly increased with postpartum insertion [<a href="#rid25">25</a>]. The use of IUDs for postpartum and postabortion contraception is reviewed separately.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/6708.html" rel="external">"Contraception: Postpartum counseling and methods"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/109209.html" rel="external">"Contraception: Postabortion", section on 'Intrauterine device'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lactating</strong> – While older, smaller studies failed to recognize any association between lactation status at time of IUD insertion and perforation risk [<a href="#rid26">26-28</a>], subsequent larger studies suggest a significantly increased risk of IUD perforation associated with lactation [<a href="#rid9">9,29-31</a>]. A large European prospective cohort study of over 61,000 people undergoing IUD insertion found that lactation status at time of IUD insertion was associated with a sixfold increase (RR 6.1, 95% CI 3.9-9.6) risk in perforation among breastfeeding versus nonbreastfeeding users with no difference between LNG and copper 380 mm<sup>2</sup> IUDs. The overall risk, however, remained small at approximately 1 percent [<a href="#rid9">9</a>]. A systematic review found that other complications related to IUD insertion including expulsion, pain, and removal requests were similar or lower for lactating IUD users compared with nonlactating users [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/6708.html" rel="external">"Contraception: Postpartum counseling and methods", section on 'Uterine perforation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distorted uterine cavity</strong> – Anatomic abnormalities, including müllerian anomalies or large intra-cavitary leiomyomas that severely distort the uterine cavity, are generally accepted relative contraindications to IUD use [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Uterine anomalies</strong> – Though there is biologic plausibility to suggest that conditions associated with uterine cavity distortion could be associated with increased risk of complications, there is limited data to support or challenge this hypothesis. There are case reports of successful IUD use in individuals with müllerian anomalies [<a href="#rid33">33,34</a>]. However, based on the limited evidence available we do not routinely advise IUD use in this population, though we recognize that it could be considered in special circumstances with appropriate counseling. (See  <a class="medical medical_review" href="/z/d/html/5418.html" rel="external">"Congenital uterine anomalies: Clinical manifestations and diagnosis", section on 'Diagnostic tools'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Uterine leiomyoma</strong> – Given the potential contraceptive and noncontraceptive benefits of IUD use (particularly hormonal IUDs) in individuals with leiomyomas and available safety profile data, we support IUD use in this population, which is consistent with the United States Centers for Disease Control and Prevention statement that the "advantages generally outweigh theoretical or proven risks" [<a href="#rid32">32</a>]. That said, we also discuss with patients that the available data suggest a possible increased risk of IUD expulsion in people with leiomyoma. Two cohort studies included in a systemic review of <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">levonorgestrel IUD</a> use among users with leiomyomas reported higher rates of IUD expulsion among users with leiomyomas (11 percent each) than among users without leiomyomas (0 and 3 percent), though the difference was not statistically significant in one study, and the other study did not test for significance [<a href="#rid35">35</a>]. The remaining six prospective noncomparative studies included in this review reported expulsion rates ranging from 0 to 20 percent. These studies, however, did not specify fibroid location or cavitary impact. There are limited data about other potential complications in this population. (See  <a class="medical medical_review" href="/z/d/html/5486.html" rel="external">"Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/5418.html" rel="external">"Congenital uterine anomalies: Clinical manifestations and diagnosis", section on 'Diagnostic tools'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors that do not increase risk</strong> – Although it has been hypothesized that uterine position or size may increase the risk of IUD complication, there are no scientific data to support this claim. In a large international IUD data set of over 5500 users, retroverted uterine position was not associated with higher rates of failure or expulsion as compared with anteverted or mid-positioned uteri [<a href="#rid36">36</a>]. Similarly, in a case-control study of 71 pregnant users with IUDs in-situ compared with 284 matched controls, uterine position was not associated with an increased risk of IUD failure resulting in pregnancy [<a href="#rid37">37</a>]. Similarly, uterine cavity length does not appear to be a risk factor for IUD failure [<a href="#rid37">37</a>] or expulsion [<a href="#rid38">38,39</a>]. Nulliparity does not affect the success rate for IUD placement [<a href="#rid3">3,4</a>].</p><p></p><p class="headingAnchor" id="H1139231610"><span class="h1">TIME OF INSERTION</span></p><p class="headingAnchor" id="H1842813373"><span class="h2">Insertional difficulties</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Techniques to reduce the chances of a difficult insertion include using a tenaculum to straighten the angle of the uterus and cervix and use of a paracervical block to reduce patient pain, the goal of reducing potential patient movement during the procedure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Straighten angle of uterus and cervix</strong> – In order to minimize risk of perforation or misplacement and to maximize provider control over the movement and angles of the cervix and uterus, a tenaculum should be placed around an adequate amount of tissue to reduce the chance of the tenaculum tearing the cervix. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Paracervical block to reduce pain</strong> – Studies report decreased pain with IUD insertion, particularly for nulliparous patients, if a paracervical block is used [<a href="#rid40">40-42</a>]. Therefore, we recommend offering a para cervical block to nulliparous patients and those at higher risk for insertional difficulties (eg, anxiety regarding IUD insertion, cervical scarring) and using shared decision-making to select block use. (See  <a class="medical medical_review" href="/z/d/html/3267.html" rel="external">"Intrauterine contraception: Insertion and removal", section on 'Preprocedure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Difficult insertion</strong> – Insertional difficulties can include challenges with identifying the cervical os (eg, individuals after loop electrosurgical excision procedure [LEEP] or cone biopsy) or with passing the sound through the cervix and internal os (eg, cervical stenosis, tortuous path of canal). Potential solutions include use of an os finder, cervical dilators, and ultrasound guidance. We find ultrasound-guided insertion particularly helpful for individuals who have had a previous difficult insertion, malposition, or expulsion or those with known or suspected distortion of the uterine cavity. These issues are addressed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3267.html" rel="external">"Intrauterine contraception: Insertion and removal", section on 'Difficult insertion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasovagal reaction</strong> – Vasovagal reactions can occur after IUD insertion and are characterized by presyncope, syncope, nausea, bradycardia, and hypotension. Most reactions are transient and resolve spontaneously. Trendelenburg position, a cool pack or cloth on the head neck or chest, and an alcohol pad under the nose for distraction and to treat nausea can all be of benefit. In rare circumstances, the vasovagal reaction may be severe enough to require an ammonia inhalant (0.3 mL) as a respiratory stimulant, or intravenous (IV) support with fluids and/or <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> (0.4 to 0.6 mL IV) in order to improve symptoms and vital signs. One-on-one continuous monitoring should be performed in these circumstances. (See  <a class="medical medical_review" href="/z/d/html/1050.html" rel="external">"Reflex syncope in adults and adolescents: Clinical presentation and diagnostic evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/111958.html" rel="external">"Reflex syncope in adults and adolescents: Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H3093874330"><span class="h2">Unexpected findings at time of placement</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Large or small uterine cavity</strong> – Extremes of uterine cavity size, generally agreed upon as size &lt;6 cm or &gt;9 cm, may create problems for IUD function and retention. The mechanism of action for the copper 380 mm<sup>2</sup> IUD is largely dependent upon approximation of the device with the uterine wall, and, thus, there is concern for decreased efficacy if this device is placed in a cavity that measures beyond 9 cm. The progestin-containing IUDs have more leeway in their positioning against the entire uterine cavity since the primary mechanism of action for these devices is to thicken cervical mucous and to cause a sterile foreign body reaction that makes the uterine cavity inhospitable to proper sperm function. Therefore, we advise patients whose uterine cavity sounds to &gt;9 cm that the copper 380 mm<sup>2</sup> IUD may be less effective, though the increased relative risk of pregnancy is not known, and the patient may want to consider an LNG 52 mg IUD or subdermal contraceptive implant instead.</p><p></p><p class="bulletIndent1">If the uterine cavity appears to measure less than 6 cm when assessed with a sound, it is possible that the sound has not traversed the internal os or across the entire length of the uterine cavity. Ultrasound assessment of the uterine cavity with the sound in place can help distinguish between a small cavity and a sound that is stuck at the level of the internal cervical os. Patients with a small uterine cavity diameter appear to have higher risk for IUD misplacement or migration that leads to an embedded device [<a href="#rid43">43</a>]. These patients are still IUD candidates. If a cavity sounds to 5 to 6 cm and the provider truly believes they are through the internal os and at the fundus, we recommend a smaller-framed IUD, such as the LNG 19.5 mg or LNG 13.5 mg devices. If the provider is unsure that they were at the uterine fundus when they measured a small uterine cavity, ultrasound evaluation should be performed to measure the uterine cavity to help with IUD candidacy determination and IUD size considerations [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – If a pelvic infection is suspected (eg, findings of cervicitis, mucopurulent discharge, cervical motion tenderness, and/or fundal tenderness on examination) at the time of IUD insertion, IUD insertion should be delayed [<a href="#rid44">44</a>]. Testing for sexually transmitted infections is performed in at-risk individuals. (See  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a>.)</p><p></p><p class="bulletIndent1">Patients diagnosed with asymptomatic gonorrhea or chlamydia cervicitis on screening at the time of IUD insertion should be treated per standard guidelines (eg, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fstd%2Ftreatment-guidelines%2Fdefault.htm&amp;token=GG%2FgjfxydbWPRfxXxvkuO3Z7rCvPfYCbHpI0XhRbEzgb1PiLFQLuos1hzlgAVwGZBa1nyF6yQEYtZyuOXda5Pg%3D%3D&amp;TOPIC_ID=5422" target="_blank">CDC Sexually Transmitted Diseases Treatment Guidelines</a>). The IUD does <strong>not</strong> need to be removed while the infection is treated [<a href="#rid44">44</a>]. While there are no large studies to help guide practice, if bacterial vaginosis, trichomoniasis, or vaginal candidiasis are diagnosed at the time of IUD insertion, the IUD can be inserted and treatment of the infection is started at the same time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incomplete insertion or partial expulsion</strong> – Occasionally, partial IUD extraction or downward misplacement (ie, the IUD stem is visible extruding from the cervix) is noticed immediately upon removal of the IUD applicator. Alternately, the clinician can accidently pull the IUD partially out of the uterus when attempting to trim the IUD strings with the scissors. If downward misplacement or partial expulsion is recognized immediately at time of placement, copper 380 mm<sup>2</sup> IUDs may be removed, reloaded into the applicator, and reinserted with a second attempt under sterile technique. However, the <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a> cannot be reloaded into the applicator. Although a small study suggests a low-lying IUD can be pushed back into place [<a href="#rid45">45</a>], we do not recommend pushing up a low-lying IUD and advise removing and replacing the device instead. </p><p></p><p class="headingAnchor" id="H1277060819"><span class="h2">Perforation</span><span class="headingEndMark"> — </span>Uterine perforation occurs when an instrument passes through the wall of the uterus and can result in visceral injury, hemorrhage, and infection. Risk factors associated with increased risk of perforation at time of IUD insertion include clinician inexperience, stenotic cervix, and immobile or retroverted uterus. The type of IUD does not appear to impact perforation risk [<a href="#rid9">9</a>]. Being postpartum and/or lactating may independently increase the risk for perforation as described above [<a href="#rid9">9,25,29,30,46-48</a>]. The incidence of perforation is reported in 1/1000, most of which likely happen at time of insertion rather than delayed migration of the device causing perforation [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/3309.html" rel="external">"Uterine perforation during gynecologic procedures"</a> and  <a class="medical medical_review" href="/z/d/html/6708.html" rel="external">"Contraception: Postpartum counseling and methods", section on 'Uterine perforation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – IUD perforation can be difficult to diagnose at time of insertion as pain and bleeding symptoms may not significantly differ from those of women who undergo uncomplicated IUD insertion. Signs and symptoms that should raise suspicion for perforation include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lack of anticipated normal fundal resistance of uterine sound or IUD applicator at time of insertion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamic instability.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe or unrelenting pelvic pain.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Active bleeding from cervical os (versus tenaculum sites) on speculum examination.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IUD string not visible or unusually short (unless IUD placed immediately postpartum).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemodynamically unstable patients</strong> – Patients with unstable vital signs, significantly worsening pain, active, heavy vaginal bleeding, or concern for intraperitoneal bleeding should be transferred to an emergency facility for further management, including possible laparoscopic exploration. Of note, hemodynamic instability is rare after a uterine perforation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemodynamically stable patients</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>IUD not deployed</strong> – Patients in whom uterine perforation by the sound or IUD is suspected and are hemodynamically stable, but the IUD has not been deployed, are further monitored for signs and/or symptoms of tachycardia, hypotension, syncope, or intraperitoneal bleeding. Patients with normal vital signs and examination can be sent home after a period of prolonged monitoring. We typically monitor vitals and serial exams every 10 to 15 minutes for a total of three assessments. Patients with unchanged examinations are sent home with teaching on worsening symptoms and symptoms that require emergency evaluation. We then follow up by phone within 48 hours. Patients who become unstable are managed as in the above bullet.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>IUD deployed</strong> – Patients in whom uterine perforation is suspected immediately following IUD deployment and who are hemodynamically stable can undergo attempted IUD removal by placing gentle traction on the string. If the IUD is not easily removed with gentle traction, operative laparoscopy should be utilized to either visually monitor and potentially correct uterine trauma while the IUD is pulled out from a vaginal approach or, to allow for abdominal localization, dissection, and removal of an IUD that is primarily in the peritoneal cavity or is involving structures, such as bowel or vessels, that may need repair. Intraoperative x-ray can be helpful to find a peritoneal IUD that is encased in adhesions or otherwise not easily visualized, especially as some peritoneal IUDs are encased in omentum that deviates cranially with intra-operative Trendelenburg positioning. Very rare cases necessitate laparotomy for peritoneal IUD localization, dissection, and removal. Given the low risk of infection and limited evidence to support the practice, we do not routinely give prophylactic antibiotics to patients with suspected uterine perforation at time of IUD placement who do not have clinical signs of infection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unclear IUD deployment</strong> – Patients in whom uterine perforation is suspected after the IUD has been deployed but placement cannot be confirmed (eg, IUD strings are not visible in the cervical os after deployment or at routine follow-up visit), are monitored as above. If this occurs at the time of IUD insertion, the IUD applicator is examined to ensure the IUD was indeed deployed and the examination field, including vagina, are inspected to ensure that the IUD did not fall out prior to insertion. If the IUD is not found extra-corporally or it is suspected that intraperitoneal placement has occurred, ultrasound is performed without delay  (<a class="graphic graphic_diagnosticimage graphicRef57867" href="/z/d/graphic/57867.html" rel="external">image 1</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the ultrasound reveals a correctly positioned intrauterine IUD, then no further action is necessary.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the IUD is not found in the uterus on initial ultrasound evaluation, a kidney, ureter, and bladder (KUB) radiograph should be performed. If the IUD is not seen on KUB, it can be assumed that the IUD was expelled. In this case, a pregnancy test and repeat contraceptive counseling are performed. If the KUB demonstrates an intraperitoneal IUD, surgical planning should be initiated for laparoscopic removal. While the surgical retrieval should be expeditious to prevent further injury, emergency removal is not required if the patient is stable. Laparotomy can be required if laparoscopic removal is not possible, if perforation of intra-abdominal organs is suspected, or if ongoing intraperitoneal hemorrhage is suspected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Future IUD insertion</strong> – Patients who have a perforation with an initial insertion attempt can have a repeat IUD insertion attempted after several weeks (two to four weeks in the authors' practices) with procedural adjuncts to avoid repeat perforation, such as ultrasound guidance. An alternate contraceptive should be used until the IUD is replaced. Given the relatively small size uterine defect associated with IUD perforation, IUD perforation is not a contraindication to labor or vaginal delivery.</p><p></p><p class="headingAnchor" id="H3867155788"><span class="h1">IMMEDIATE POST-INSERTION: 0 TO 7 DAYS</span><span class="headingEndMark"> — </span>We educate patients that vaginal bleeding and cramping uterine pain are common side effects in the first week after IUD insertion. We also discuss warning sides for pelvic infection, although this complication is uncommon.</p><p class="headingAnchor" id="H68166671"><span class="h2">Post-insertion bleeding</span><span class="headingEndMark"> — </span>Minor trauma from IUD insertion, including tenaculum placement and abrasion of the cervix by the IUD, commonly results in post-procedural bleeding. Most patients have at least some degree of spotting or bleeding immediately after IUD insertion, though data specific to initial bleeding patterns after IUD insertion are sparse. A study of 160 users who received the copper T-200 reported that 94 percent of users had bleeding immediately after IUD insertion, that mean duration of initial bleeding was 4.5±2.4 days, and that users required a mean of 3.5±2.5 pads per day [<a href="#rid49">49</a>].</p><p>Patient education and reassurance regarding normal bleeding are paramount. We counsel patients that post-procedural bleeding should not be much heavier than a normal period, may be prolonged in timing, and can even blend directly into the prolonged or abnormal uterine bleeding that happens in the first three to six months of IUD use as the uterine lining synchronizes to the presence of a new LNG or copper 380 mm<sup>2</sup> IUD. We generally do not use prophylactic medication as the abnormal bleeding typically resolves quickly and most users do well with advance education and supportive counseling  (<a class="graphic graphic_figure graphicRef113217" href="/z/d/graphic/113217.html" rel="external">figure 1</a>). However, some experts treat patients prophylactically with nonsteroidal anti-inflammatory drugs (NSAIDs) or the antifibrinolytic <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> to reduce the amount of bleeding associated with initial copper 380 mm<sup>2</sup> IUD use. Pretreatment with <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> has not been shown to be helpful [<a href="#rid50">50</a>]. (See <a class="local">'Irregular bleeding and/or cramping'</a> below.)</p><p>Patients who report heavy bleeding, commonly described as soaking through a pad or more per hour, should be evaluated quickly, as this could be a sign of partial expulsion, uterine perforation, or cervical laceration.</p><p class="headingAnchor" id="H3631961447"><span class="h2">Uterine cramping or pain</span><span class="headingEndMark"> — </span>Post-procedural cramping is very common after IUD insertion regardless of IUD type. The mild to moderate discomfort or pain that occurs with insertion lessens within minutes for almost all patients [<a href="#rid51">51-54</a>]. Most patients report some ongoing cramping upon leaving the office, though at levels and patterns significantly less than those experienced peri-insertion. In one study of 59 subjects who underwent IUD insertion, 86 percent required over-the-counter analgesics for cramping symptoms, but only 11 to 13 percent required medication for more than five days [<a href="#rid54">54</a>]. We advise NSAIDs (ie, <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> at doses of 600 to 800 mg every six to eight hours) and heating pads as needed for discomfort. Individuals who develop significantly worsening pain not improved with NSAIDs should be seen for urgent evaluation, as this could be a sign of complication such as partial expulsion, malposition, uterine perforation, or pelvic infection.</p><p class="headingAnchor" id="H2660797382"><span class="h2">Infection and/or pelvic inflammatory disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk</strong> –<strong> </strong>Historically there have been concerns that IUD use increases the risk of pelvic inflammatory disease (PID). However, extensive epidemiologic study, clinical trials and systematic reviews do not support this concern. While gonorrhea and chlamydia infection are associated with PID, rates of PID are similar among asymptomatic infected patients whether or not they have an IUD. Rates of PID in asymptomatic infected individuals range from 0 to 5 percent, while PID rates among uninfected individuals range from 0 to 2 percent [<a href="#rid55">55,56</a>]. Infection attributable to the insertion process is rare, as demonstrated by the following studies and trial:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one international study including over 22,000 users, the risk of infection was just under 1 percent within the first 20 days after insertion and rare thereafter with a cumulative risk of 0.1 percent [<a href="#rid7">7</a>]. Moreover, the risk of PID did not increase with prolonged use. Subsequent large United States studies have estimated the risk of PID after IUD insertion to be 0.5 percent in the first 3 to 6 months [<a href="#rid5">5,6</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a United States population screened for gonorrhea and chlamydia either before or at the time of IUD insertion, the risk of PID within the first 90 days after insertion was 1.1 per 1000 women [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a trial of over 2500 IUD users, LNG 52 mg IUD users had a significantly lower rates of PID than copper 380 mm<sup>2</sup> IUD users over a three-year period, which suggests the <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a> may have a protective effect against PID [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of HIV infection</strong> – HIV infection does not appear to affect risk of infection associated with IUD insertion. A 2016 systemic review of six studies found low rates of PID among IUD users with HIV and no increased rate of infection complications, HIV transmission, viral shedding, or disease progress in this population based on limited evidence [<a href="#rid59">59</a>]. The CDC Medical Eligibility Criteria for Contraception classified IUD use among women with HIV as a category 2 (advantages outweigh potential risks) [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Although PID resulting from IUD insertion is rare, given the possible serious sequelae of PID, clinicians should have a low threshold for empiric treatment of PID in individuals who have recently undergone IUD insertion. The diagnosis and treatment of PID are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment with IUD in situ</strong> – Most individuals with an IUD in situ who are diagnosed with PID do not require IUD removal prior to initiation of antibiotic therapy, regardless of interval since IUD insertion  (<a class="graphic graphic_algorithm graphicRef114453" href="/z/d/graphic/114453.html" rel="external">algorithm 1</a>). In a systematic review that included three randomized trials and a prospective cohort study, one cohort study and one trial reported shorter hospitalization duration for the patients who left their IUDs in place, one trial reported no laboratory differences among individuals treated with or without the IUD in situ, and one trial reported that those who underwent IUD removal during treatment "experienced improved recovery in most clinical signs and symptoms" compared with users who retained their IUDs [<a href="#rid61">61</a>]. Based on these data, the Centers for Disease Control and Prevention (CDC) US Selected Practice Recommendations for Contraceptive Use recommend that individuals with an IUD and PID should be started on appropriate antibiotic therapy with the IUD in place [<a href="#rid62">62</a>]. </p><p></p><p class="bulletIndent2">Patients who are treated for PID and have an IUD in-situ should have close clinical follow up within 48 to 72 hours to ensure improvement. Those with persistent or worsening signs or symptoms should undergo ultrasound to evaluate for tubo-ovarian abscess and initiation of parenteral antibiotic therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment and IUD removal</strong> – IUD removal is performed for patients with PID with known actinomycoses or those who do not respond to therapy in the setting of an in situ IUD. As actinomyces flourishes on foreign bodies, such as the IUD [<a href="#rid63">63</a>], possible actinomyces infection requires prompt removal of the IUD to improve treatment and recovery. (See  <a class="medical medical_review" href="/z/d/html/13997.html" rel="external">"Treatment of actinomycosis", section on 'IUD associated infections'</a>.)</p><p></p><p class="bulletIndent2">Patients who are at high risk for severe infection (eg, immunocompromised) may benefit from IUD removal, although the optimal approach for this patient population is not known. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of IUD culture</strong> – The IUD can be sent for microbiologic culture at the time of removal. However, we reserve IUD culture for patients who do not adequately respond to routine antibiotic therapy as there are no data to inform the accuracy or clinical significance of this approach.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of future IUD insertion</strong> – For patients who have been treated for documented intra-uterine infection and had their IUD removed, IUD reinsertion timing should be delayed for 12 weeks [<a href="#rid32">32</a>]. We advise that the IUD insertion be delayed until the treatment course is complete, the symptoms are resolved, and the pelvic examination is normal in the setting of cervicitis alone. Due to the high risk of reinfection, the CDC recommends repeat testing for gonorrhea or chlamydia infection at three months from the original infection [<a href="#rid44">44</a>].</p><p></p><p class="headingAnchor" id="H1485814189"><span class="h1">EARLY POST-INSERTION: 0 TO 3 MONTHS</span></p><p class="headingAnchor" id="H3093729610"><span class="h2">Irregular bleeding and/or cramping</span><span class="headingEndMark"> — </span>Irregular (and/or heavy) bleeding and cramping are the most common patient concerns in the first few months after IUD placement, regardless of IUD type  (<a class="graphic graphic_figure graphicRef113217" href="/z/d/graphic/113217.html" rel="external">figure 1</a>). In a self-reported survey study of IUD users, increased bleeding and cramping was experienced in 15 percent and 32 percent of LNG 52 mg users and 71 percent and 63 percent of copper 380 mm<sup>2</sup> IUD users at three months after IUD insertion [<a href="#rid64">64</a>]. However, by six months following insertion, 62 percent of LNG 52 mg users reported lighter bleeding and 81 percent of copper 380 mm<sup>2</sup> IUD users reported lighter or no change in bleeding patterns. Despite the altered bleeding patterns, 94 percent of LNG 52 mg IUD users and 93 percent of copper 380 mm<sup>2</sup> IUD users reported being somewhat or very satisfied with their IUD method. Counseling regarding expected bleeding changes prior to IUD insertion may improve patients' expectations and satisfaction, largely by selecting only those patients who understand and accept potential inconvenient short-term bleeding. Overall, most patients are reassured to know that bleeding does not indicate a decrease in contraceptive efficacy, that the bleeding is not dangerous, and that the symptoms will likely improve with time. For most individuals, supportive counseling is an adequate intervention. (See  <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Impact of device type on bleeding pattern'</a>.)</p><p>However, patients who continue to have heavy and/or prolonged bleeding are evaluated to exclude IUD malposition or expulsion, pregnancy, infection, and cervical dysplasia (see <a class="local">'Anytime post-insertion'</a> below). We offer medical treatment to patients who continue to have bothersome bleeding from IUD insertion, and we discuss that supporting data for these approaches are mostly lacking.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">Levonorgestrel IUD</a><strong> users</strong> – For patients with continued bleeding with an LNG IUD, treatment options include a trial of nonsteroidal anti-inflammatory drugs (NSAIDs), combined estrogen/progestin hormonal contraception, and progestin-only pills  (<a class="graphic graphic_table graphicRef113197" href="/z/d/graphic/113197.html" rel="external">table 1</a>). In the absence of supporting data, we take the following approach based on the risks of undesired side effects, ease of use, availability, and cost. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NSAID</strong> – While we typically treat bothersome bleeding with combined hormonal contraceptives, patients with contraindications to estrogen or who desire a non-hormonal treatment option are offered <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> 800 mg every eight hours, which may reduce bleeding and cramping by inhibiting prostaglandin production. A trial of ibuprofen can be continued for one to three cycles or months. Alternate NSAID options include <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a> 500 mg twice daily for five days or <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a> 50 mg taken three times daily for five days. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Combined hormonal contraceptive</strong> – For patients who accept combined hormonal contraceptives or for those in whom NSAID therapy is not helpful, contraindicated, or declined, we prefer a combined hormonal contraceptive (oral pill, transdermal patch, or vaginal ring). We start with an initial trial of one to three cycles. Patients who respond well can then stop the medication or continue if desired. As there are no data on the optimal pill for this indication, choice of pill is determined by patient preference, drug availability, and insurance coverage. Theoretically, the use of combined hormonal methods help synchronously thin the endometrial lining. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">Tranexamic acid</a> – For individuals who continue to have bothersome bleeding, we offer tranexamic acid 1300 mg three times daily for up to five days (the medication can be stopped sooner than five days if the bleeding stops). Two studies have supported use of 500 mg or 650 mg doses given three to four times a day up to five days, if these are available [<a href="#rid65">65,66</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Progestin-only therapy</strong> – Lastly, if the bothersome bleeding continues or if the patient is not a candidate for estrogen therapy, the last option is a progestin-only pill such as <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> 0.35 mg taken daily for one to three months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Copper 380 mm</strong><strong><sup>2</sup></strong><strong> IUD users</strong> – For patients with continued bleeding with a copper 380 mm<sup>2</sup> IUD, treatment options that have been studied include NSAID medications, combined estrogen-progestin contraception or progestin-only pills, the fibrinolysis inhibitor <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a>, and the antidiuretic <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a>  (<a class="graphic graphic_table graphicRef113193" href="/z/d/graphic/113193.html" rel="external">table 2</a>) [<a href="#rid65">65</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NSAIDs</strong> – While we typically treat bothersome bleeding with combined hormonal contraceptives, patients with contraindications to estrogen or who desire a non-hormonal treatment option are offered <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> 800 mg every eight hours to reduce bleeding and cramping. Alternate NSAID options include <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a> and <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a> as for <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a> above. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hormonal contraception</strong> – For patients who accept hormonal contraceptives or for those in whom NSAID therapy is not helpful, contraindicated, or declined, we offer a trial of a hormonal contraceptive method to be used in combination with the IUD. While we prefer combined hormonal contraceptives (oral pill, transdermal patch, vaginal ring), progestin-only methods can be reasonable used. The choice is based on the patient's preferences and risk factors for estrogen use. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">Tranexamic acid</a><strong> </strong>– For individuals who continue to have bothersome bleeding, we offer tranexamic acid 1300 mg three times daily for up to five days (the medication can be stopped sooner than five days if the bleeding stops). Two studies have supported use of 500 mg or 650 mg doses, if these are available [<a href="#rid65">65,66</a>].  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting data</strong> – A trial comparing <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> (400 mg three times) daily with placebo in 28 users starting the copper 380 mm<sup>2</sup> IUD reported that users receiving ibuprofen noted less menstrual blood loss, although both groups reported increased menstrual bleeding relative to pre-IUD insertion (2 percent increase for ibuprofen users versus 74 percent for placebo users) [<a href="#rid67">67</a>]. In a trial of 175 Chinese individuals that compared two doses of <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> (500 mg and 1000 mg) twice daily with placebo following IUD insertion, both groups receiving tranexamic acid reported less menstrual blood loss [<a href="#rid68">68</a>]. There was no difference in blood loss between the high- and low-dose groups. In a trial of 19 individuals comparing tranexamic acid (1500 mg three times a day for five days), <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a> (50 mg three times on the first day followed by 25 mg three times daily for four days, for two periods), and placebo, tranexamic acid was associated with the greatest reduction in menstrual blood flow, although a reduction was also noted with diclofenac [<a href="#rid69">69</a>].</p><p></p><p class="headingAnchor" id="H895783362"><span class="h2">Infection</span><span class="headingEndMark"> — </span>If an infection such as endometritis or pelvic inflammatory disease is going to occur, the most common time of infection is near the time of insertion. However, infection can rarely develop later. Management of infection in a patient with an IUD is the same regardless of the time point from insertion. (See <a class="local">'Infection and/or pelvic inflammatory disease'</a> above.)</p><p class="headingAnchor" id="H259257735"><span class="h2">Problems noted at time of follow-up examination</span><span class="headingEndMark"> — </span>The authors do not routinely recommend a follow-up visit after IUD insertion as studies have not demonstrated a benefit. However, it is reasonable to offer a visit for IUD surveillance several weeks after insertion for patients who desire as it allows the provider an opportunity to assess the patient's satisfaction with the device and identify any unwanted side effects or complications. The following issues can be identified during a routine post-insertion check or at any time a speculum examination is performed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpalpable strings</strong> – Patients are no longer routinely advised to check their IUD strings on a regular basis because there is no evidence to support this practice [<a href="#rid62">62,70</a>]. However, some people check strings to confirm the IUD is in place. Given the rare but serious sequelae from an unrecognized IUD perforation or early expulsion, patients with concerns for nonpalpable strings should be seen in a timely fashion for pelvic examination to confirm IUD string presence. If the IUD strings are not visible extruding from the cervix, ultrasound examination is performed to identify the IUD location  (<a class="graphic graphic_diagnosticimage graphicRef57867" href="/z/d/graphic/57867.html" rel="external">image 1</a>). (See <a class="local">'Perforation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonvisible strings</strong> – If the IUD strings are not visible on speculum examination, a cytobrush can be placed in the cervix and gently twisted in attempt to pull the strings down and out of the cervical os. If these maneuvers are not successful, we then perform an ultrasound to localize the IUD  (<a class="graphic graphic_diagnosticimage graphicRef57867" href="/z/d/graphic/57867.html" rel="external">image 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals whose IUD is confirmed as being in the correct location by ultrasound, no further intervention or surveillance is necessary. </p><p class="bulletIndent2"><span class="glyph">•</span>For individuals whose IUD is not visible in the uterus by ultrasound, we perform additional imaging to exclude possible uterine perforation. (See <a class="local">'Perforation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expulsion</strong> – While IUD expulsion can occur at any time, expulsion is more likely to happen within the first months after insertion. In a study of over 2100 users who underwent IUD insertion, the mean expulsion rates were 1 percent at one month of follow-up and 4 percent at one year [<a href="#rid3">3</a>]. The management of IUD expulsion is discussed in detail below. (See <a class="local">'Expulsion'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perforation</strong> –<strong> </strong>While perforation is frequently diagnosed at time of occurrence, delayed diagnosis can be made if the IUD strings are no longer visible at the time of speculum examination. (See <a class="local">'Perforation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Partner feels strings</strong> – On occasion, patients report that their sexual partners can feel the IUD strings at time of intercourse, which can be irritating or painful for the partner. At time of insertion, we suggest cutting the strings at least 2 cm long to leave enough length for the strings to curve around the face of the cervix. With time, the IUD strings typically both soften and curve around along the cervix to project towards the cervical-vaginal fornix instead of along the length of the vagina. If the partner is aware of the strings but not bothered by them, no intervention is needed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Long strings</strong> – For patients whose IUD strings are bothering a sexual partner, a Scopette or clamp can be used to direct the string ends to the posterior vaginal fornix. Additionally, if there is enough length, the strings can be re-cut with curved scissors to make sure that they are cut on the perpendicular; when the strings are cut on the bias with straight scissors there may be greater risk for partner discomfort. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Short strings or continued partner discomfort</strong> – If the partner continues to be irritated by the strings after the above interventions, the strings can instead be cut flush with the external cervical os to completely minimize the risk of the partner feeling them. Prior to such trimming, the patient should be counseled about the potential need for increased intervention (such as dilation and extraction with graspers or office hysteroscopy) at time of IUD removal should the strings be cut flush with the cervix.</p><p></p><p class="headingAnchor" id="H1644153901"><span class="h1">ANYTIME POST-INSERTION</span></p><p class="headingAnchor" id="H2819906374"><span class="h2">Continued bleeding and cramping</span><span class="headingEndMark"> — </span>While most patients note a reduction in irregular bleeding and cramping with IUD use over time, some level of continued bleeding and cramping is common, but the patterns vary with the IUD type  (<a class="graphic graphic_figure graphicRef113217" href="/z/d/graphic/113217.html" rel="external">figure 1</a>). Individuals with copper 380 mm<sup>2</sup> IUDs maintain menstrual cyclicity and have reported a 55 to 74 percent increase in the amount of menstrual bleeding, likely due to increased endogenous prostaglandin release in response to the IUD [<a href="#rid67">67,71</a>]. The progestin-containing IUDs are typically associated with decreased bleeding and/or amenorrhea, with 44 percent of LNG 19.5 mg users reporting amenorrhea at six months of use and 50 percent reporting amenorrhea at 12 and 24 months [<a href="#rid72">72</a>]. However, unscheduled or heavy bleeding still occurs in individuals with <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a>. By 12 months of use, 4 percent of LNG 19.5 mg users reported frequent or prolonged bleeding [<a href="#rid71">71</a>]. For patients with either type of IUD who continue to have ongoing heavy bleeding and cramping three months or more from insertion, we evaluate them to exclude IUD malposition or expulsion, pregnancy, and cervical dysplasia. (See  <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Impact of device type on bleeding pattern'</a> and <a class="local">'Malpositioned IUD'</a> below and <a class="local">'Pregnancy'</a> below and <a class="local">'Cervical dysplasia'</a> below.)</p><p></p><p>Once the IUD position is confirmed and other complications have been excluded, we do the following for individuals who continue to have unacceptable bleeding patterns more than three months after IUD insertion:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">Levonorgestrel IUD</a><strong> users</strong> – Patients with LNG IUD-induced heavy or unscheduled bleeding are offered medical therapy with NSAIDs, <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a>, and <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a>  (<a class="graphic graphic_table graphicRef113197" href="/z/d/graphic/113197.html" rel="external">table 1</a>) [<a href="#rid65">65</a>]. Dosing includes <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a> 500 mg twice daily for five days, tranexamic acid 1300 mg three times a day for up to five days (the medication is stopped when the uterine bleeding stops, typically around four days of treatment), or a single monthly dose of mifepristone 100 mg. We do not prescribe mefenamic, estrogen, or <a class="drug drug_general" data-topicid="15626" href="/z/d/drug information/15626.html" rel="external">ulipristal</a> acetate because these agents have been associated with either no improvement (<a class="drug drug_general" data-topicid="9601" href="/z/d/drug information/9601.html" rel="external">mefenamic acid</a>) or increased bleeding (estrogen and ulipristal acetate. The matrix metalloproteinase (MMP) inhibitor <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> has been studied as a treatment for heavy or irregular bleeding associated with other progestin-only contraceptive methods, but never in patients using the progestin-containing IUD [<a href="#rid73">73,74</a>]. Possible etiologies of the irregular or prolonged bleeding associated with the progestin-containing IUDs include dilation and fragility of superficial capillaries in the setting of a thinned endometrium, changes in the structural support of the endometrium, and changes in the MMP activity [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Copper 380 mm</strong><strong><sup>2</sup></strong><strong> IUD users</strong> – Patients with copper 380 mm<sup>2</sup> IUD-induced heavy menstrual bleeding are offered medical therapy, including treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), the fibrinolytic agent <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a>, and the antidiuretic <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a>  (<a class="graphic graphic_table graphicRef113193" href="/z/d/graphic/113193.html" rel="external">table 2</a>) [<a href="#rid65">65</a>]. Of note, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> should not be used for these individuals as it is associated with increased menstrual bleeding in copper 380 mm<sup>2</sup> IUD users [<a href="#rid75">75</a>]. (See <a class="local">'Irregular bleeding and/or cramping'</a> above.)</p><p></p><p class="headingAnchor" id="H2022035321"><span class="h2">Malpositioned IUD</span><span class="headingEndMark"> — </span>Malposition refers to IUDs that are displaced into the lower uterine segment, partially expelled into the cervix, rotated on their axis, embedded in the myometrium, or partially or completely protruding through the uterine serosa. The true incidence of malpositioned IUDs is not known, but one review of over 17,000 ultrasound evaluations performed at a single academic institution reported a rate of 10 percent [<a href="#rid2">2</a>]. Malpositioned IUDs are more likely to cause symptoms of pain or abnormal bleeding and the abnormal position is typically diagnosed with ultrasound evaluation [<a href="#rid76">76</a>]. The use of coronal plane evaluation with three dimensional ultrasound may provide improved diagnosis of malposition not otherwise noticed with a two-dimensional longitudinal view  (<a class="graphic graphic_diagnosticimage graphicRef113207" href="/z/d/graphic/113207.html" rel="external">image 2</a> and <a class="graphic graphic_diagnosticimage graphicRef62490" href="/z/d/graphic/62490.html" rel="external">image 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Regardless of symptoms, for patients whose malpositioned IUD is partially or completely protruding through the uterine serosa or displaced into the cervical canal so far that the IUD stem can be seen on vaginal examination, the IUD should be removed and replaced, if desired. These malpositions may be associated with an increased risk of contraceptive failure and potential sequelae of the malposition (eg, organ perforation). In a study comparing pregnant and nonpregnant users with a copper 380 mm<sup>2</sup> IUD in place, the risk of malposition was much higher in the pregnant group (64 versus 11 percent) [<a href="#rid77">77</a>]. However, one important limitation is that it is not known if the malpositioned IUDs resulted in pregnancy or if the growth of the pregnancy contributed to the malpositioning of the IUD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are symptomatic (eg, pain and/or bleeding) and with a malpositioned IUD (ie, those displaced in the lower uterine segment, rotated on their axis, or partially embedded in the myometrium), we remove the IUD and replace it with a new IUD (if desired by the patient), often under ultrasound guidance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For asymptomatic patients with an incidentally identified malpositioned IUD that is located within the uterus but does not extend into the cervix (ie, those displaced in the lower uterine segment, rotated on their axis, or partially embedded in the myometrium), we do not routinely recommend IUD removal, as the IUD is likely still highly effective based on mechanism of action, although further research is needed in this area. While the displacement could lessen the contraceptive efficacy, the absolute risk of pregnancy when a progestin or <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">copper IUD</a> is malpositioned but within the uterus appears to be low. Supporting data include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a case control study that evaluated copper 380 mm<sup>2</sup> IUD location in 25 pregnant patients with IUD in situ compared with 97 patients evaluated post device insertion, pregnant patients had a much higher incidence of cervically located IUDs (52 percent [13 in 25] versus 7 percent [7 in 97]) [<a href="#rid78">78</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A second study of patients with a copper 380 mm<sup>2</sup> IUD in place compared 318 early pregnant individuals with 300 control patients and reported a higher incidence of malpositioned IUD in the pregnant individuals (64 versus 11 percent) [<a href="#rid77">77</a>]. However, in both of these studies, it is not clear if the malpositioned IUDs resulted in pregnancy or if the growth pregnancy contributed to the IUDs becoming malpositioned.</p><p></p><p class="bulletIndent1">Additionally, many IUDs in the lower uterine segment will spontaneously move to a proper fundal location over time [<a href="#rid79">79-81</a>]. Furthermore, given the low rate of highly effective contraception reinitiation after malpositioned IUD removal, removal is associated with a higher pregnancy rate than retention of malpositioned IUD [<a href="#rid2">2</a>]. In keeping with the American College of Obstetricians and Gynecologists (ACOG) committee opinion, we advise appropriate patient counseling and a shared-decision making model [<a href="#rid82">82</a>].</p><p></p><p class="headingAnchor" id="H3108373607"><span class="h2">Expulsion</span><span class="headingEndMark"> — </span>IUD expulsion is when the device is expelled from the uterus. Expulsions can be partial (device protruding from the external cervical os or present in the cervical canal on imaging) or complete (device located in the vagina, not present in the uterus or abdomen on imaging, or with documented patient report of the device being found outside the body) [<a href="#rid83">83</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong> – Symptoms suggestive of IUD expulsion include cramping, dyspareunia, vaginal discharge or bleeding, or pregnancy and its accompanying symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary expulsion</strong> – The incidence of IUD expulsion during the first year of use is [<a href="#rid3">3,19-21,84</a>]: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Copper 380 mm<sup>2 </sup>IUD – 2 to 10 percent </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">Levonorgestrel</a> IUDs – 2 to 6 percent </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Repeat expulsion </strong>– Individuals who have previously expelled an IUD are at higher risk of a repeat expulsion should a new IUD be placed. Rates of repeat IUD expulsion after prior expulsion range from 14 to 31 percent [<a href="#rid3">3,85</a>]. The cause(s) for the increased expulsion risk following a prior expulsion is not clearly known, but possible explanations include anatomical factors (eg, severe flexion), abnormally shaped uterine cavity, patulous internal cervical os, or provider insertional technique that put a subset of women at increased risk for serial expulsion. Interestingly, a prior expulsion may be a risk factor for increased contraceptive failure and resultant pregnancy even if the IUD remains in situ [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for IUD expulsion</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Increased risk</strong> – Reported risk factors for IUD expulsion include prior expulsion, heavy menstrual bleeding, dysmenorrhea, postpartum status, insertion following later abortion, and prior all-vaginal deliveries [<a href="#rid83">83,87-90</a>]. In a retrospective US health record study including over 228,000 patients with an IUD insertion and no delivery in the prior 52 weeks, the factors most associated with increased risk of IUD expulsion (adjusted analysis) were recent or past heavy menstrual bleeding, excess body weight (overweight or obesity), younger age (highest risk in patients aged 20 years or younger), and parity of four or more [<a href="#rid83">83</a>]. In the study, nearly 81 percent of patients had a <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">levonorgestrel IUD</a> while approximately 19 percent had a copper 380 mm<sup>2</sup> IUD. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No impact on risk</strong> – Nulliparity, length of the endometrial cavity, and placement after a first-trimester abortion do not increase this risk [<a href="#rid3">3,4,18,38,39,90-93</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – IUD expulsion is typically confirmed with ultrasound imaging demonstrating an empty uterus. In some cases, the patient will see the device in their underwear or the toilet.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repeat IUD insertion</strong> – Individuals who have had an IUD expulsion can have a new device inserted if desired and are counseled that repeat expulsion rates of over 14 percent have been reported [<a href="#rid3">3,85</a>]. If a second expulsion occurs and the patient wants a third attempt, we suggest evaluating the uterine cavity prior to placement with hysteroscopy or sonography. </p><p></p><p class="bulletIndent1">If there is suspicion for uterine fibroids or severe ante- or retroversion, we place the IUD using ultrasound guidance to ensure fundal positioning. It is unknown if changing the IUD type reduces the risk of a repeat expulsion. (See  <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">"Intrauterine contraception: Candidates and device selection", section on 'Contraindications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reinsertion of partially expulsed device</strong> – For patients with a partially expulsed IUD (vertical arm extending partially or fully through the cervical canal), limited data suggest reinsertion may be possible using ultrasound guidance. In a small observational study of 55 patients with a partially expelled IUD, 51 (92.7 percent) had the IUD successfully repositioned under ultrasound guidance and nine (17.6 percent) experienced re-expulsion [<a href="#rid45">45</a>]. The reinsertion procedure did not require antibiotics or paracervical anesthesia. While no injuries or uterine infections were reported in the study, the small sample size limits definitive conclusions. We do not use this approach because of concerns for possible infection and/or device fracture.</p><p></p><p class="headingAnchor" id="H3753291601"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>IUDs are highly effective contraceptives with a failure rate comparable to permanent sterilization. A database study including over 18 million hospital deliveries reported a retained IUD was present in 12 per 100,000 births [<a href="#rid94">94</a>]. While the overall risk of pregnancy with an IUD is less than 1 percent, the risk of IUD failure resulting in pregnancy is the highest within the first year after IUD insertion and ranges from 0.2 to 0.8 percent [<a href="#rid8">8</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for IUD failure include young age (possibly secondary to increased fertility), IUD malposition, and prior IUD expulsion (even if the current IUD is in the correct location) [<a href="#rid13">13,26,86</a>]. Other risk factors include grand multiparity, obesity, and previous uterine scar [<a href="#rid94">94</a>]. The risk of pregnancy also varies by IUD type [<a href="#rid77">77</a>]. Uterine position and size are not associated with increased risk of pregnancy [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ectopic</strong> – Although the absolute risk of ectopic pregnancy is lower for individuals using an IUD compared with noncontracepting people or those using other reversible contraceptives [<a href="#rid95">95</a>], patients who become pregnant with an IUD in situ are at a higher risk for ectopic pregnancy compared with the general population [<a href="#rid96">96,97</a>]. Diagnosis and management of ectopic pregnancy is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Copper versus </strong><a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a> – When pregnancies occur, the likelihood of ectopic implantation appears to be lower among <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">copper IUD</a> users than LNG IUD users. Reported rates of ectopic pregnancy among IUD users who conceive ranges from 11 to 15 percent for copper 380 mm<sup>2</sup> IUD users to 27 to 53 percent for the LNG 52 mg IUD users [<a href="#rid9">9,21,65</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk by </strong><a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUD</a><strong> type</strong> – In a national database study of over 963,000 females using contraception, the adjusted absolute rate of ectopic pregnancy per 10,000 person-years was 7.7 for LNG 52 mg, 7.1 for LNG 19.5 mg, and 15.7 for LNG 13.5 mg [<a href="#rid98">98</a>]. For comparison, patients using other hormonal contraception experienced 2.4 ectopic pregnancies per 10,000 person years. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management</strong> – Patients with a pregnancy and an IUD in place should undergo ultrasound assessment of IUD location and whatever evaluation is needed for the ectopic pregnancy. If the IUD needs to be removed as part of the ectopic diagnosis, such as for uterine aspiration, the patient can have a new IUD inserted during or after the ectopic management. Patients whose IUD is found to be malpositioned should have it removed, and a new one inserted as desired. Patients with a normally located IUD can leave the IUD in place despite the contraceptive failure or elect a different IUD or contraceptive method, as desired. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intrauterine pregnancy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risks</strong> – Intrauterine pregnancies conceived with an IUD in-situ are associated with both increased maternal and fetal risks compared with the general population [<a href="#rid94">94</a>]. Maternal risk is primarily related to infection and includes septic abortion and chorioamnionitis. Fetal risks include miscarriage, preterm premature rupture of membranes, preterm birth, fetal malpresentation, and intrauterine fetal demise [<a href="#rid94">94</a>]. Though there is theoretical risk of fetal exposure to <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a>, there does not appear to be increased risk of congenital anomalies associated with a retained <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUD</a> [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Chorioamnionitis</strong> – People who conceive an intrauterine pregnancy with an IUD in place are at increased risk of chorioamnionitis [<a href="#rid100">100,101</a>]. Removal of IUD early in pregnancy appears to reduce, but not eliminate, this risk. A retrospective study comparing nearly 300 pregnant subjects with a copper 380 mm<sup>2</sup> IUD in situ with pregnant controls without an IUD reported a rising rate of clinical chorioamnionitis dependent on IUD presence and management (chorioamnionitis in 0.7 percent of pregnant controls, 4 percent in pregnant subjects who had the IUD removed, and 7 percent for pregnant subjects who kept the IUD in situ) [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/z/d/html/6762.html" rel="external">"Clinical chorioamnionitis"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Miscarriage</strong> – The miscarriage rate associated with retained IUD has been reported as high as 47 to 57 percent [<a href="#rid102">102-104</a>]. Early IUD removal or expulsion appears to be associated with decreased risk of miscarriage, ranging from 20 to 54 percent [<a href="#rid104">104</a>]. Furthermore retained IUD also appears to be associated with an increased risk of later (after 12 week) miscarriage versus non-IUD users [<a href="#rid100">100</a>]. (See  <a class="medical medical_review" href="/z/d/html/5439.html" rel="external">"Pregnancy loss (miscarriage): Terminology, risk factors, and etiology"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Preterm birth</strong> – Similar to chorioamnionitis and miscarriage, removal of IUD in early pregnancy appears reduce, but not eliminate, the increased risk of preterm birth associated with an IUD and intrauterine pregnancy. A retrospective study of nearly 200 pregnant subjects with retained copper 380 mm<sup>2</sup> IUDs (n = 196) compared with pregnant control subjects reported a more than fivefold increased risk of preterm birth for subjects with the retained IUD [<a href="#rid100">100</a>]. In the above retrospective study that assessed chorioamnionitis, preterm birth occurred in 14 percent of subjects who had an early IUD removal and 18 percent of subjects who retained the IUD, compared with a 7 percent rate of preterm birth in pregnant controls [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/z/d/html/6798.html" rel="external">"Preterm labor: Clinical findings, diagnostic evaluation, and initial treatment"</a> and  <a class="medical medical_review" href="/z/d/html/6761.html" rel="external">"Spontaneous preterm birth: Overview of risk factors and prognosis"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Abruption</strong> – Concomitant pregnancy and intrauterine IUD has been associated with an increased risk of placental abruption [<a href="#rid100">100,101</a>]. (See  <a class="medical medical_review" href="/z/d/html/6826.html" rel="external">"Acute placental abruption: Pathophysiology, clinical features, diagnosis, and consequences"</a> and  <a class="medical medical_review" href="/z/d/html/6803.html" rel="external">"Acute placental abruption: Management and long-term prognosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management</strong> – Management of intrauterine pregnancy in the setting of an IUD depends on pregnancy intentions and IUD location. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Undesired pregnancy</strong> – For individuals who desire termination in setting of in situ IUD, IUD removal should be performed prior to medical termination or at the time of surgical termination. The IUD can be replaced as desired immediately after surgical termination. (See  <a class="medical medical_review" href="/z/d/html/109209.html" rel="external">"Contraception: Postabortion"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Pregnancy continuation</strong> – For patients interested in pregnancy continuation, we remove the IUD as early as possible if the IUD strings are visible or if the IUD in within the cervix, which is consistent with American College of Obstetrics and Gynecology, US Centers for Disease Control and Prevention, and US Food and Drug Administration recommendations [<a href="#rid62">62,82,99</a>]. Given increased risk of infection if the pregnancy is being continued, we give <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> 500 mg orally for one dose following IUD removal during pregnancy. </p><p></p><p class="bulletIndent3">There is limited evidence to guide management for women who desire pregnancy continuation when IUD strings are not visible and the IUD is not in the cervix. The 2017 ACOG Practice Bulletin advises counseling patients about risks of IUD retention but not attempting IUD removal in this situation [<a href="#rid105">105</a>]. Given increased maternal and fetal risks associated with continuing a pregnancy with an IUD in situ (eg, sepsis), we favor a shared decision-making model. If the IUD strings are not visible, the patient desires IUD removal, and IUD is inferior to the pregnancy, it is reasonable to try IUD removal under ultrasound guidance with Bozeman uterine packing forceps, a curved Kelly forceps, IUD hook, or alligator forceps as described below. (See <a class="local">'Issues and complications at time of removal'</a> below.)</p><p></p><p class="bulletIndent3">Hysteroscopic IUD removal can also be attempted for patients who desire to continue their pregnancy and have the IUD removed. Successful hysteroscopic IUD removal has been described and is a reasonable option for individuals with low-lying IUDs or IUDs that are distal to an intrauterine pregnancy [<a href="#rid106">106,107</a>]. However, there is insufficient evidence to universally support this practice, as it is unclear if this invasive procedure poses greater or less threat of pregnancy loss than retained IUD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IUD replacement</strong> – For individuals who become pregnant with an IUD in place, the pregnancy and the IUD can be managed as outlined below, and the patient remains a candidate for a repeat IUD as desired.</p><p></p><p class="headingAnchor" id="H2773726074"><span class="h2">IUD discontinuation</span><span class="headingEndMark"> — </span>Bleeding and cramping are the common reasons cited for copper 380 mm<sup>2</sup> IUD removal. However, with the <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a>, change in bleeding patterns accounts for approximately one-third of discontinuations while two-thirds are due to systemic side effects, with similar rates reported for the LNG 13.5 mg as compared with the LNG 19.5 mg [<a href="#rid108">108,109</a>]. Demographers from the longitudinal National Survey of Family Growth (NSFG) estimate that the typical individual who continuously uses reversible contraceptive methods from their 15<sup>th</sup> to their 45<sup>th</sup> birthday will discontinue the contraceptive method nearly 10 times due to method-related reasons [<a href="#rid110">110</a>]. While the rate of IUD discontinuation is lower than that for other contraceptive methods, the rate of IUD removal by United States individuals during their first year of IUD use ranges from 20 (LNG IUDs) to 22 (copper 380 mm<sup>2 </sup>IUD) percent [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H908884481"><span class="h2">Hormonal side effects</span><span class="headingEndMark"> — </span>Common progestin-related complaints include acne, weight change, hirsutism, headache, nausea, and mood changes [<a href="#rid58">58,96</a>]. While the progestin effect of the <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUD</a> is primarily local, circulating <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a> from the LNG 19.5 mg can be detected at levels of approximately one-fifth that of individuals using a daily combined oral contraceptive pill, with 150 mcg of levonorgestrel [<a href="#rid111">111-113</a>]. While some individuals can be sensitive to even low levels of hormones, this low levonorgestrel level is generally well tolerated and causes few side effects. In a prospective study comparing weight change over 12 months among people electing progestin-based contraceptives (LNG IUD, <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">etonogestrel implant</a>, and depot <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a>) or the copper 380 mm<sup>2</sup> IUD, there was no difference in the weight changes among the groups in the adjusted analysis [<a href="#rid114">114</a>]. In a Danish national register study that reviewed the records of over one million people, the initiation of an antidepressant was more common among users of progestin-only contraceptives, the LNG IUD included, as compared with nonhormonal contraceptive users [<a href="#rid115">115</a>]. However, it is not known if this association is causal. Lastly, one prospective study of new start IUD users and one cross-sectional analysis of hormonal contraceptive users reported no decrease in sexual desire or sexual function in LNG IUD users [<a href="#rid116">116,117</a>].</p><p>Whether the systemic side effects reported by individuals are real or perceived by them to be due to the <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUD</a> is often irrelevant. All concerns should be validated, education should be provided, and shared decision-making should be performed. Treatment of side effects while leaving the IUD in place is a potential option depending on the patient, their other contraceptive options or concerns, and the degree to which these symptoms affect their daily life.</p><p class="headingAnchor" id="H2151855172"><span class="h2">Cervical dysplasia</span><span class="headingEndMark"> — </span>People with an IUD in place are not at increased risk of cervical dysplasia, though benign changes of inflammation and metaplasia are seen more commonly. Intrauterine devices do not increase risk of cervical cancer and may potentially even be protective against cervical dysplasia and malignancy [<a href="#rid118">118</a>]. Conditions that increase the risk for cervical cancer, like human immunodeficiency virus, are not contraindications to IUD use [<a href="#rid119">119</a>]. Routine cervical dysplasia and cancer screening should be performed for patients with IUDs as those without as recommended by the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.asccp.org%2Fguidelines&amp;token=uGGGJzyXPE4G4L0UBsgY9hJjKXB4mkqox9FODDu3F7WoJC%2FCsUPSUXmJ17kSSoCJ&amp;TOPIC_ID=5422" target="_blank">American Society for Colposcopy and Cervical Pathology</a>.</p><p>We take the following approach for patients with Pap smear abnormalities:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cervix biopsy and/or endocervical curettage</strong> – For patients who require a biopsy with Kevorkian forceps, the biopsy can usually be done with the IUD in place without additional maneuvers. Similarly, an endocervical curettage can be done while gently moving the IUD string to minimize the risk of their disruption. We counsel patients about risk of accidental IUD removal or expulsion with ECC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LEEP procedure</strong> – For patients who require a loop electrosurgical excision procedure (LEEP), the procedure can be done with the aid of one of several maneuvers to keep the IUD in place.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One option is to cut two separate cervical segments while protecting the strings. With this method we use a Scopette to deviate the strings up to the 12 o'clock position of the cervix and cut the first cervical specimen halfway up the cervix on the posterior aspect of the cervix. Then, similarly deviate the IUD strings towards the 6 o'clock position to allow a second specimen to be cut from the anterior aspect of the cervix.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A second method is to feed the strings through a hollow tube, such as the sheath of a spinal needle in order to protect the strings while a two specimen LEEP is collected.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Third, the strings may be gently tucked up into the cervix temporarily with the help of a cytobrush, the LEEP specimen can be collected, and then the IUD strings can be teased back down through the external os.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lastly, the strings can be disregarded, the LEEP can be performed cutting the strings with the pass of the loop, and the IUD can be managed moving forward like any other intrauterine IUD with missing strings.</p><p></p><p class="headingAnchor" id="H1747845940"><span class="h2">Actinomyces and related organisms</span><span class="headingEndMark"> — </span><em>Actinomyces</em> is part of the normal gastrointestinal flora. Limited evidence also suggests that asymptomatic female genital colonization is not uncommon. In a review of over 20,000 Pap smears,<em> Actinomyces</em>-like organisms were seen on 0.26 percent of smears [<a href="#rid120">120</a>]. Up to 7 percent of IUD users will have a Pap smear report documenting <em>Actinomyces</em>-like organisms [<a href="#rid63">63,121</a>]. However, the Pap smear is not the most specific test for <em>Actinomyces</em>; of all the <em>Actinomyces</em> diagnoses that made with Pap smear, only half are truly culture positive when cervical culture is performed [<a href="#rid63">63,122</a>]. While culture is the gold standard for identification of <em>Actinomyces</em>, it is not routinely useful [<a href="#rid63">63</a>]. </p><p>There are no data for or against performing a cervical culture to confirm diagnosis once <em>Actinomyces</em> is identified on Pap smear in asymptomatic individuals. For those with an IUD who are found to have <em>Actinomyces</em> on a Pap smear, we evaluate for signs and/or symptoms of pelvic inflammatory disease (PID) and base our treatment approach on the findings of that evaluation [<a href="#rid105">105,123</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>For patients with an IUD who have <em>Actinomyces</em> or <em>Actinomyces</em>-like organism on Pap smear but without signs and/or symptoms of PID, we leave the IUD in place and do not perform a cervical culture [<a href="#rid105">105</a>]. We discuss the findings with the patient and make her aware of the limitations of testing and recommend evaluation if she develops pelvic pain or vaginal discharge.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <em>Actinomyce</em>s is incidentally noted on Pap smear and the patient has signs of symptoms concerning for PID, we remove the IUD, send the IUD for culture, and obtain a pelvic ultrasound to evaluate for abscess. If <em>Actinomyces</em> is cultured from the IUD, we treat the patient with penicillin in addition to empiric PID treatment, as per <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fstd%2Ftreatment-guidelines%2FSTI-Guidelines-2021.pdf&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLMtWRdy7GNFvGuwQhc910NNu2wbNgOglz26TRIMXNoFGogKt5bmn64ZotwjLo7COhPS9s628zqZLb%2FXtHEaywYw%3D&amp;TOPIC_ID=5422" target="_blank">United States Centers for Disease Control and Prevention 2015 STD Treatment Guidelines</a>. Choice of antibiotic regimen for treatment of abdominopelvic <em>Actinomyces</em> infection is discussed further in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16419.html" rel="external">"Management and complications of tubo-ovarian abscess", section on 'Actinomyces or rare pathogens'</a> and  <a class="medical medical_review" href="/z/d/html/2691.html" rel="external">"Abdominal actinomycosis"</a>.)</p><p></p><p class="headingAnchor" id="H1538473528"><span class="h1">ISSUES AND COMPLICATIONS AT TIME OF REMOVAL</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonvisualized strings</strong> – IUD strings are not visible at the external cervical os on speculum examination in 4 to 18 percent of patients at the time of IUD check or removal [<a href="#rid124">124-127</a>]. The differential diagnosis for nonvisualized IUD strings on speculum examination includes IUD in situ, unrecognized IUD expulsion, malposition such as IUD embedding in the uterine fundus, and IUD perforation.</p><p></p><p class="bulletIndent1">For people who desire IUD removal but have nonvisible IUD strings, we take the following approach to identifying the strings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>First, we attempt to tease the strings out of the external os by inserting and rotating a cytobrush into the endocervix. This technique has a reported efficacy of 98 percent and can be performed regardless of concern for pregnancy or intentions for IUD removal versus continuation [<a href="#rid68">68,69</a>]. While using a colposcope to visualize the strings within the cervix has been reported [<a href="#rid128">128-130</a>], the authors do not find this technique helpful.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If string retrieval with the cytobrush is not successful, there is no concern for pregnancy, and the patient is able to tolerate continued attempts, string identification (and IUD removal) can be attempted using a Bozeman uterine packing forceps, disposable thread finder, a curved Kelly forceps, IUD hook, or alligator forceps. A cervical block may help keep the patient comfortable during the additional instrumentation of the cervix.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients in whom cervical instrumentation does not identify the strings, and depending on the patient's ability to tolerate cervical manipulation, we place a tenaculum and, if needed, dilate the cervix to 21 french (ie, 7mm) with a Pratt dilator to facilitate opening the forceps to grasp the string. A paracervical block (10 to 20 cc 1% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> or <a class="drug drug_general" data-topicid="9245" href="/z/d/drug information/9245.html" rel="external">chloroprocaine</a>, either without <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>) could be employed to improve success and comfort at initial clinic removal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If IUD removal remains unsuccessful, pelvic ultrasound should be performed to confirm IUD location  (<a class="graphic graphic_diagnosticimage graphicRef57867" href="/z/d/graphic/57867.html" rel="external">image 1</a>). Once intrauterine position is confirmed, these methods can be attempted again either in the office or outpatient surgical setting, depending on the patient's needs for sedation. In a prospective study of 29 parous individuals who presented for LNG 52 mg IUD removal without visible strings, 100 percent were able to have their IUD removed in office on first visit using an IUD hook, Kelly clamp, or other blunt grasper, or ring forceps with or without adjuvant ultrasound guidance and/or cervical anesthetic [<a href="#rid131">131</a>]. In a second study of 23 subjects with failed initial IUD removal, 83 percent had successful removal with the addition of ultrasound guidance alone [<a href="#rid130">130</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients in whom the above techniques are not successful in identifying the IUD strings or if ultrasound evaluation reveals an IUD embedded in the uterine wall, hysteroscopic evaluation and removal can be necessary, either in an office or outpatient surgical setting. After appropriate cervical anesthesia and dilation, the operative hysteroscope is passed through the cervix and gently advanced into the uterus until the IUD or strings are visualized. Once visualized, the hysteroscopic grasper is used to grasp the strings (preferable if they are seen) or the device, and the IUD, grasper, and hysteroscope can all be withdrawn concurrently from the cervix.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Difficult removal</strong> – Approaches to remove an IUD include using additional traction, pelvic ultrasonography to confirm IUD location, and hysteroscopic removal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IUD strings visible</strong> – If IUD strings are visible at the external os, but the device cannot be removed with traditional gentle traction, increased moderate traction can be applied to the IUD strings. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Broken IUD strings</strong> – If the IUD still cannot be removed with moderate traction or if the strings either feel like they are breaking or actually do break off the device, a pelvic ultrasound, preferably with 3D images, is obtained to confirm IUD location (if not already performed)  (<a class="graphic graphic_diagnosticimage graphicRef57867" href="/z/d/graphic/57867.html" rel="external">image 1</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>IUD stem visible</strong> – If the IUD stem is visible, a Kelly clamp, or similar, can be used to grasp and remove the IUD. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Role of hysteroscopic removal</strong> – If ultrasound confirms intrauterine position but the IUD is unable to be removed, we perform hysteroscopic removal, similar to patients whose IUD strings are not visible. (See <a class="local">'Problems noted at time of follow-up examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suspected myometrial IUD</strong> – For IUDs known or suspected on ultrasound to be embedded in the fundal myometrium but not perforating through the serosa, we recommend trial of traditional removal in the office, as a case series study of 157 subjects reported that only 10 percent of all IUDs diagnosed as embedded on preoperative imaging were confirmed to be embedded on hysteroscopy [<a href="#rid132">132</a>]. If moderate traction does not remove the embedded IUD, we perform hysteroscopic removal to ensure complete, atraumatic IUD removal. If the embedded IUD portion looks like it might break with traction, it can be teased or dug out of the myometrium with the closed grasper. Once more, if the IUD is visible, it can be regrasped at a portion distal to the weak point in the device and removed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Broken IUD</strong> – IUD breakage is rare and limited to case reports. Most cases occurred during IUD removal when the IUD fractured and resulted in a retained arm, but there are also rare cases reporting spontaneous expulsion of a portion of a fractured IUD [<a href="#rid133">133</a>]. There are limited data on the consequences of leaving an IUD fragment in situ, including abnormal bleeding, pain, infertility, and infection. For patients who are symptomatic or who want the fragment removed, the location can be diagnosed with ultrasonography, hysteroscopy, or a kidney, ureter, bladder (KUB) x-ray. Asymptomatic patients are counseled that long term sequela of leaving an IUD fragment in utero has unknown possible future consequences. For patients who desire future fertility, we advise fragment removal if the fragments are visible on imaging or hysteroscopy. Options for removal of retained fragments include manual vacuum aspiration, an IUD hook, narrow tip forceps, and hysteroscopic-assisted extraction [<a href="#rid133">133</a>]. For myometrial IUD fragments that cannot be easily removed with hysteroscopy, one author (KP) advises leaving the fragment in place as it is unlikely to impact fertility, although the data to inform this approach are limited.</p><p></p><p class="headingAnchor" id="H1262795393"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112268.html" rel="external">"Society guideline links: Contraception"</a>.)</p><p class="headingAnchor" id="H4208966862"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/86384.html" rel="external">"Patient education: Intrauterine devices (IUDs) (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86385.html" rel="external">"Patient education: Long-acting methods of birth control (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/141006.html" rel="external">"Patient education: IUD insertion (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/141007.html" rel="external">"Patient education: IUD removal (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H526369677"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse events</strong> – Serious IUD complications are uncommon and include expulsion, pelvic inflammatory disease (PID), contraceptive failure, with increased risk of ectopic pregnancy if failure does occur, and perforation. Less serious side effects include malposition, pain, and irregular bleeding. (See <a class="local">'Prevalence of complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for IUD complications include young age, postpartum or postabortion insertion, breastfeeding, and a distorted uterine cavity. (See <a class="local">'Risk factors for complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of symptom timing on range of adverse events</strong> – The differential of adverse events associated with IUDs varies based on the timing of the event relative to the timing of the IUD insertion. Some symptoms can occur in multiple time settings (ie, vaginal bleeding).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>At time of</strong> <strong>IUD insertion</strong> – Difficult IUD insertion, vasovagal reaction, unexpected findings such as infection, partial expulsion or extraction of the IUD, and perforation can all be encountered at the time of IUD insertion. (See <a class="local">'Time of insertion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Week following IUD insertion</strong> – IUD side effects that commonly occur in the first week following insertion include post-insertion bleeding and uterine cramping or pain. Abnormal bleeding and cramping are typically self-limited and resolve within three months. Very rarely, infection such as pelvic inflammatory disease develops. Most women with an IUD in-situ who are diagnosed with PID do not require IUD removal regardless of interval since IUD insertion  (<a class="graphic graphic_algorithm graphicRef114453" href="/z/d/graphic/114453.html" rel="external">algorithm 1</a>). The one exception is users with known actinomyces PID. As actinomyces flourishes on foreign bodies, such as the IUD, actinomyces PID requires prompt removal of the IUD to improve treatment and recovery. (See <a class="local">'Immediate post-insertion: 0 to 7 days'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Early postinsertion</strong> – Early postinsertion issues include continued bothersome bleeding, infection, and problems that are noted at the time of a follow-up examination, such as missing IUD strings, IUD expulsion, or perforation. (See <a class="local">'Early post-insertion: 0 to 3 months'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>At any time following IUD insertion</strong> – Events that can occur any time after IUD insertion include continued bothersome bleeding, IUD malposition or expulsion, pregnancy, and hormonal side effects. Because of these issues, some individuals will desire IUD removal. In addition, individuals with an IUD can be diagnosed with cervical dysplasia or actinomyces, which requires additional treatment. (See <a class="local">'Anytime post-insertion'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Ectopic pregnancy</strong> – Patients with an ectopic pregnancy and an IUD in place undergo ultrasound assessment of IUD location and whatever evaluation is needed for the ectopic pregnancy. (See <a class="local">'Pregnancy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Intrauterine pregnancy</strong> – Patients with an intrauterine pregnancy and IUD are advised to have the IUD removed at the time of diagnosis based on the increased risk of poor maternal and fetal outcomes associated with a retained IUD and the reduction of risk associated with IUD removal early in pregnancy. (See <a class="local">'Pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Challenges with IUD removal</strong> – Issues and complications that can occur at the time of IUD removal include nonvisible IUD strings, difficult IUD removals, and, rarely, a broken IUD. These can typically be managed with a variety of techniques in the office setting. In some cases, hysteroscopy can be required to remove a retained, embedded, or broken IUD. (See <a class="local">'Issues and complications at time of removal'</a> above.)</p><p></p><p class="headingAnchor" id="H497314865"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Gillian Dean, MD, MPH, and Alisa B Goldberg, MD, MPH, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Creinin M, Kohn JE, Tang JH, et al. Society of Family Planning Committee statement on IUD nomenclature. Contraception 2022; 106:1.</a></li><li><a class="nounderline abstract_t">Braaten KP, Benson CB, Maurer R, Goldberg AB. Malpositioned intrauterine contraceptive devices: risk factors, outcomes, and future pregnancies. Obstet Gynecol 2011; 118:1014.</a></li><li><a class="nounderline abstract_t">Aoun J, Dines VA, Stovall DW, et al. Effects of age, parity, and device type on complications and discontinuation of intrauterine devices. Obstet Gynecol 2014; 123:585.</a></li><li><a class="nounderline abstract_t">Madden T, McNicholas C, Zhao Q, et al. Association of age and parity with intrauterine device expulsion. Obstet Gynecol 2014; 124:718.</a></li><li><a class="nounderline abstract_t">Sufrin CB, Postlethwaite D, Armstrong MA, et al. Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstet Gynecol 2012; 120:1314.</a></li><li><a class="nounderline abstract_t">Birgisson NE, Zhao Q, Secura GM, et al. Positive testing for Neisseria gonorrhoeae and Chlamydia trachomatis and the risk of pelvic inflammatory disease in IUD users. J Womens Health (Larchmt) 2015; 24:354.</a></li><li><a class="nounderline abstract_t">Farley TM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices and pelvic inflammatory disease: An international perspective. Lancet 1992; 339:785.</a></li><li><a class="nounderline abstract_t">Trussell J. Contraceptive failure in the United States. Contraception 2011; 83:397.</a></li><li><a class="nounderline abstract_t">Heinemann K, Reed S, Moehner S, Minh TD. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices. Contraception 2015; 91:274.</a></li><li class="breakAll">Jensen JT, Creinin MD. Speroff &amp; Darney’s Clinical Guide to Contraception, 6th ed, Wolters Kluwer Health, Philadelphia 2019.</li><li><a class="nounderline abstract_t">Grunloh DS, Casner T, Secura GM, et al. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol 2013; 122:1214.</a></li><li><a class="nounderline abstract_t">Dragoman MV, Simmons KB, Paulen ME, Curtis KM. Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review. Contraception 2017; 95:117.</a></li><li><a class="nounderline abstract_t">Berenson AB, Tan A, Hirth JM, Wilkinson GS. Complications and continuation of intrauterine device use among commercially insured teenagers. Obstet Gynecol 2013; 121:951.</a></li><li><a class="nounderline abstract_t">Simonatto P, Bahamondes MV, Fernandes A, et al. Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system. J Obstet Gynaecol Res 2016; 42:554.</a></li><li><a class="nounderline abstract_t">Teal SB, Romer SE, Goldthwaite LM, et al. Insertion characteristics of intrauterine devices in adolescents and young women: success, ancillary measures, and complications. Am J Obstet Gynecol 2015; 213:515.e1.</a></li><li><a class="nounderline abstract_t">Teal SB, Sheeder J. IUD use in adolescent mothers: retention, failure and reasons for discontinuation. Contraception 2012; 85:270.</a></li><li><a class="nounderline abstract_t">Jatlaoui TC, Riley HEM, Curtis KM. The safety of intrauterine devices among young women: a systematic review. Contraception 2017; 95:17.</a></li><li><a class="nounderline abstract_t">Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. Contraception 1999; 60:155.</a></li><li><a class="nounderline abstract_t">Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception 1997; 56:341.</a></li><li><a class="nounderline abstract_t">Sivin I, Schmidt F. Effectiveness of IUDs: A review. Contraception 1987; 36:55.</a></li><li><a class="nounderline abstract_t">Mechanism of action, safety and efficacy of intrauterine devices. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1987; 753:1.</a></li><li><a class="nounderline abstract_t">Grimes DA, Lopez LM, Schulz KF, et al. Immediate post-partum insertion of intrauterine devices. Cochrane Database Syst Rev 2010; :CD003036.</a></li><li><a class="nounderline abstract_t">Grimes DA, Lopez LM, Schulz KF, Stanwood NL. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst Rev 2010; :CD001777.</a></li><li><a class="nounderline abstract_t">Jacob NS, Mahnert N, Livingston JB, et al. Comparison of intrauterine device expulsion rates after aspiration abortion or interval insertion. Obstet Gynecol 2014; 123 Suppl 1:10S.</a></li><li><a class="nounderline abstract_t">Reed SD, Zhou X, Ichikawa L, et al. Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study. Lancet 2022; 399:2103.</a></li><li><a class="nounderline abstract_t">Chi IC, Kelly E. Is lactation a risk factor of IUD- and sterilization-related uterine perforation? A hypothesis. Int J Gynaecol Obstet 1984; 22:315.</a></li><li><a class="nounderline abstract_t">Chi I, Feldblum PJ, Rogers SM. IUD--related uterine perforation: an epidemiologic analysis of a rare event using an international dataset. Contracept Deliv Syst 1984; 5:123.</a></li><li><a class="nounderline abstract_t">Chi IC, Wilkens LR, Champion CB, et al. Insertional pain and other IUD insertion-related rare events for breastfeeding and non-breastfeeding women--a decade's experience in developing countries. Adv Contracept 1989; 5:101.</a></li><li><a class="nounderline abstract_t">Heartwell SF, Schlesselman S. Risk of uterine perforation among users of intrauterine devices. Obstet Gynecol 1983; 61:31.</a></li><li><a class="nounderline abstract_t">Berry-Bibee EN, Tepper NK, Jatlaoui TC, et al. The safety of intrauterine devices in breastfeeding women: a systematic review. Contraception 2016; 94:725.</a></li><li><a class="nounderline abstract_t">Armstrong MA, Raine-Bennett T, Reed SD, et al. Association of the Timing of Postpartum Intrauterine Device Insertion and Breastfeeding With Risks of Intrauterine Device Expulsion. JAMA Netw Open 2022; 5:e2148474.</a></li><li><a class="nounderline abstract_t">Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li><a class="nounderline abstract_t">Espey E, Ogburn T, Hall R, Byrn F. Use of intrauterine device in the setting of uterus didelphys. Obstet Gynecol 2006; 108:774.</a></li><li><a class="nounderline abstract_t">Eskew AM, Crane EK. Levonorgestrel Intrauterine Device Placement in a Premenopausal Breast Cancer Patient with a Bicornuate Uterus. J Minim Invasive Gynecol 2016; 23:133.</a></li><li><a class="nounderline abstract_t">Zapata LB, Whiteman MK, Tepper NK, et al. Intrauterine device use among women with uterine fibroids: A systematic review. Contraception 2010; 82:41.</a></li><li><a class="nounderline abstract_t">Chi IC, Farr G, Dominik R, Robinson N. Do retroverted uteri adversely affect insertions and performance of IUDs? Contraception 1990; 41:495.</a></li><li><a class="nounderline abstract_t">Avecilla-Palau A, Moreno V. Uterine factors and risk of pregnancy in IUD users: a nested case-control study. Contraception 2003; 67:235.</a></li><li><a class="nounderline abstract_t">Bahamondes MV, Monteiro I, Canteiro R, et al. Length of the endometrial cavity and intrauterine contraceptive device expulsion. Int J Gynaecol Obstet 2011; 113:50.</a></li><li><a class="nounderline abstract_t">Liang H, Li L, Yuan W, et al. Dimensions of the endometrial cavity and intrauterine device expulsion or removal for displacement: a nested case-control study. BJOG 2014; 121:997.</a></li><li><a class="nounderline abstract_t">Mody SK, Farala JP, Jimenez B, et al. Paracervical Block for Intrauterine Device Placement Among Nulliparous Women: A Randomized Controlled Trial. Obstet Gynecol 2018; 132:575.</a></li><li><a class="nounderline abstract_t">Akers AY, Steinway C, Sonalkar S, et al. Reducing Pain During Intrauterine Device Insertion: A Randomized Controlled Trial in Adolescents and Young Women. Obstet Gynecol 2017; 130:795.</a></li><li><a class="nounderline abstract_t">Perez-Lopez FR, Martinez-Dominguez SJ, Perez-Roncero GR, Hernandez AV. Uterine or paracervical lidocaine application for pain control during intrauterine contraceptive device insertion: a meta-analysis of randomised controlled trials. Eur J Contracept Reprod Health Care 2018; 23:207.</a></li><li><a class="nounderline abstract_t">Shipp TD, Bromley B, Benacerraf BR. The width of the uterine cavity is narrower in patients with an embedded intrauterine device (IUD) compared to a normally positioned IUD. J Ultrasound Med 2010; 29:1453.</a></li><li><a class="nounderline abstract_t">Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.</a></li><li><a class="nounderline abstract_t">Yamaguti EMM, Sontag Dos Reis ET, Martins WP, et al. Ultrasound-guided repositioning technique for partially expelled intrauterine device: descriptive feasibility study. Ultrasound Obstet Gynecol 2023; 61:109.</a></li><li><a class="nounderline abstract_t">Caliskan E, Oztürk N, Dilbaz BO, Dilbaz S. Analysis of risk factors associated with uterine perforation by intrauterine devices. Eur J Contracept Reprod Health Care 2003; 8:150.</a></li><li><a class="nounderline abstract_t">Van Houdenhoven K, van Kaam KJ, van Grootheest AC, et al. Uterine perforation in women using a levonorgestrel-releasing intrauterine system. Contraception 2006; 73:257.</a></li><li><a class="nounderline abstract_t">Kaislasuo J, Suhonen S, Gissler M, et al. Intrauterine contraception: incidence and factors associated with uterine perforation--a population-based study. Hum Reprod 2012; 27:2658.</a></li><li><a class="nounderline abstract_t">Ylikorkala O, Kauppila A, Siljander M. Anti-prostglandin therapy in prevention of side-effects of intrauterine contraceptive devices. Lancet 1978; 2:393.</a></li><li><a class="nounderline abstract_t">Cohen MA, Simmons KB, Edelman AB, Jensen JT. Tamoxifen for the prevention of unscheduled bleeding in new users of the levonorgestrel 52-mg intrauterine system: a randomized controlled trial. Contraception 2019; 100:391.</a></li><li><a class="nounderline abstract_t">Ngo LL, Braaten KP, Eichen E, et al. Naproxen Sodium for Pain Control With Intrauterine Device Insertion: A Randomized Controlled Trial. Obstet Gynecol 2016; 128:1306.</a></li><li><a class="nounderline abstract_t">Ngo LL, Ward KK, Mody SK. Ketorolac for Pain Control With Intrauterine Device Placement: A Randomized Controlled Trial. Obstet Gynecol 2015; 126:29.</a></li><li><a class="nounderline abstract_t">Abbas AM, Abdellah MS, Khalaf M, et al. Effect of cervical lidocaine-prilocaine cream on pain perception during copper T380A intrauterine device insertion among parous women: A randomized double-blind controlled trial. Contraception 2017; 95:251.</a></li><li><a class="nounderline abstract_t">Rapkin RB, Achilles SL, Schwarz EB, et al. Self-Administered Lidocaine Gel for Intrauterine Device Insertion in Nulliparous Women: A Randomized Controlled Trial. Obstet Gynecol 2016; 128:621.</a></li><li><a class="nounderline abstract_t">Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception 2006; 73:145.</a></li><li><a class="nounderline abstract_t">Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000; 356:1013.</a></li><li><a class="nounderline abstract_t">Walsh T, Grimes D, Frezieres R, et al. Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. Lancet 1998; 351:1005.</a></li><li><a class="nounderline abstract_t">Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 1991; 77:261.</a></li><li><a class="nounderline abstract_t">Tepper NK, Curtis KM, Nanda K, Jamieson DJ. Safety of intrauterine devices among women with HIV: a systematic review. Contraception 2016; 94:713.</a></li><li class="breakAll">US Medical Eligibility Criteria (US MEC) for Contraceptive Use, 2016. https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/summary.html. (Accessed on January 30, 2019).</li><li><a class="nounderline abstract_t">Tepper NK, Steenland MW, Gaffield ME, et al. Retention of intrauterine devices in women who acquire pelvic inflammatory disease: a systematic review. Contraception 2013; 87:655.</a></li><li><a class="nounderline abstract_t">Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li><a class="nounderline abstract_t">Westhoff C. IUDs and colonization or infection with Actinomyces. Contraception 2007; 75:S48.</a></li><li><a class="nounderline abstract_t">Diedrich JT, Desai S, Zhao Q, et al. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol 2015; 212:50.e1.</a></li><li><a class="nounderline abstract_t">Friedlander E, Kaneshiro B. Therapeutic Options for Unscheduled Bleeding Associated with Long-Acting Reversible Contraception. Obstet Gynecol Clin North Am 2015; 42:593.</a></li><li><a class="nounderline abstract_t">Alanwar A, Abbas AM, Hussain SH, et al. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial. Eur J Contracept Reprod Health Care 2018; 23:365.</a></li><li><a class="nounderline abstract_t">Mäkäräinen L, Ylikorkala O. Ibuprofen prevents IUCD-induced increases in menstrual blood loss. Br J Obstet Gynaecol 1986; 93:285.</a></li><li><a class="nounderline abstract_t">Lin X, Gao ES, Li D, et al. Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstet Gynecol Scand 2007; 86:1126.</a></li><li><a class="nounderline abstract_t">Ylikorkala O, Viinikka L. Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. Br J Obstet Gynaecol 1983; 90:78.</a></li><li><a class="nounderline abstract_t">Melo J, Tschann M, Soon R, et al. Women's willingness and ability to feel the strings of their intrauterine device. Int J Gynaecol Obstet 2017; 137:309.</a></li><li><a class="nounderline abstract_t">Suvisaari J, Lähteenmäki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. Contraception 1996; 54:201.</a></li><li><a class="nounderline abstract_t">Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002; 65:129.</a></li><li><a class="nounderline abstract_t">Weisberg E, Hickey M, Palmer D, et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod 2006; 21:295.</a></li><li><a class="nounderline abstract_t">Weisberg E, Hickey M, Palmer D, et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009; 24:1852.</a></li><li><a class="nounderline abstract_t">Pedrón N, Lozano M, Gallegos AJ. The effect of acetylsalicylic acid on menstrual blood loss in women with IUDs. Contraception 1987; 36:295.</a></li><li><a class="nounderline abstract_t">Benacerraf BR, Shipp TD, Bromley B. Three-dimensional ultrasound detection of abnormally located intrauterine contraceptive devices which are a source of pelvic pain and abnormal bleeding. Ultrasound Obstet Gynecol 2009; 34:110.</a></li><li><a class="nounderline abstract_t">Inal MM, Ertopçu K, Ozelmas I. The evaluation of 318 intrauterine pregnancy cases with an intrauterine device. Eur J Contracept Reprod Health Care 2005; 10:266.</a></li><li><a class="nounderline abstract_t">Anteby E, Revel A, Ben-Chetrit A, et al. Intrauterine device failure: relation to its location within the uterine cavity. Obstet Gynecol 1993; 81:112.</a></li><li><a class="nounderline abstract_t">Tangtongpet O, Choktanasiri W, Patrachai S, Israngura Na Ayudhya N. Intrauterine location and expulsion of intrauterine device. Thai Journal of Obstetrics and Gynaecology 2003; 15:45.</a></li><li><a class="nounderline abstract_t">Morales-Roselló J. Spontaneous upward movement of lowly placed T-shaped IUDs. Contraception 2005; 72:430.</a></li><li><a class="nounderline abstract_t">Faundes D, Perdigao A, Faundes A, et al. T-shaped IUDs accomodate to their position during the first three months after insertion. Contraception 2000; 62:165.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice, Long-Acting Reversible Contraceptive Expert Work Group. Committee Opinion No 672: Clinical Challenges of Long-Acting Reversible Contraceptive Methods. Obstet Gynecol 2016; 128:e69.</a></li><li><a class="nounderline abstract_t">Anthony MS, Zhou X, Schoendorf J, et al. Demographic, Reproductive, and Medical Risk Factors for Intrauterine Device Expulsion. Obstet Gynecol 2022; 140:1017.</a></li><li><a class="nounderline abstract_t">Gatz JL, Armstrong MA, Postlethwaite D, et al. Association between intrauterine device type and risk of perforation and device expulsion: results from the Association of Perforation and Expulsion of Intrauterine Device study. Am J Obstet Gynecol 2022; 227:57.e1.</a></li><li><a class="nounderline abstract_t">Bahamondes L, Díaz J, Marchi NM, et al. Performance of copper intrauterine devices when inserted after an expulsion. Hum Reprod 1995; 10:2917.</a></li><li><a class="nounderline abstract_t">Thonneau P, Almont T, de La Rochebrochard E, Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. Hum Reprod 2006; 21:2612.</a></li><li><a class="nounderline abstract_t">Keenahan L, Bercaw-Pratt JL, Adeyemi O, et al. Rates of Intrauterine Device Expulsion Among Adolescents and Young Women. J Pediatr Adolesc Gynecol 2021; 34:362.</a></li><li><a class="nounderline abstract_t">Okusanya BO, Oduwole O, Effa EE. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst Rev 2014; :CD001777.</a></li><li><a class="nounderline abstract_t">Steenland MW, Tepper NK, Curtis KM, Kapp N. Intrauterine contraceptive insertion postabortion: a systematic review. Contraception 2011; 84:447.</a></li><li><a class="nounderline abstract_t">Gilliam ML, Jensen JT, Eisenberg DL, et al. Relationship of parity and prior cesarean delivery to levonorgestrel 52 mg intrauterine system expulsion over 6 years. Contraception 2021; 103:444.</a></li><li><a class="nounderline abstract_t">Zhang J, Feldblum PJ, Chi IC, Farr MG. Risk factors for copper T IUD expulsion: an epidemiologic analysis. Contraception 1992; 46:427.</a></li><li><a class="nounderline abstract_t">Steenland MW, Zapata LB, Brahmi D, et al. Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review. Contraception 2013; 87:611.</a></li><li><a class="nounderline abstract_t">Bednarek PH, Creinin MD, Reeves MF, et al. Immediate versus delayed IUD insertion after uterine aspiration. N Engl J Med 2011; 364:2208.</a></li><li><a class="nounderline abstract_t">Panchal VR, Rau AR, Mandelbaum RS, et al. Pregnancy with retained intrauterine device: national-level assessment of characteristics and outcomes. Am J Obstet Gynecol MFM 2023; 5:101056.</a></li><li><a class="nounderline abstract_t">Xiong X, Buekens P, Wollast E. IUD use and the risk of ectopic pregnancy: a meta-analysis of case-control studies. Contraception 1995; 52:23.</a></li><li><a class="nounderline abstract_t">Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: A multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994; 61:70.</a></li><li><a class="nounderline abstract_t">Sivin I, Stern J, Diaz J, et al. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices. Contraception 1987; 35:245.</a></li><li><a class="nounderline abstract_t">Meaidi A, Torp-Pedersen C, Lidegaard Ø, Mørch LS. Ectopic Pregnancy Risk in Users of Levonorgestrel-Releasing Intrauterine Systems With 52, 19.5, and 13.5 mg of Hormone. JAMA 2023; 329:935.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 121: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol 2011; 118:184.</a></li><li><a class="nounderline abstract_t">Kim SK, Romero R, Kusanovic JP, et al. The prognosis of pregnancy conceived despite the presence of an intrauterine device (IUD). J Perinat Med 2010; 38:45.</a></li><li><a class="nounderline abstract_t">Ganer H, Levy A, Ohel I, Heiner E. Pregnancy outcome in women with an intrauterine contraceptive device. Am J Obstet Gynecol 2009; 4:38.</a></li><li><a class="nounderline abstract_t">Shine RM, Thompson JF. The in situ IUD and pregnancy outcome. Am J Obstet Gynecol 1974; 119:124.</a></li><li><a class="nounderline abstract_t">Koetsawang S, Rachawat D, Piya-Anant M. Outcome of pregnancy in the presence of intrauterine device. Acta Obstet Gynecol Scand 1977; 56:479.</a></li><li><a class="nounderline abstract_t">Tatum HJ, Schmidt FH, Jain AK. Management and outcome of pregnancies associated with the Copper T intrauterine contraceptive device. Am J Obstet Gynecol 1976; 126:869.</a></li><li><a class="nounderline abstract_t">Committee on Practice Bulletins-Gynecology, Long-Acting Reversible Contraception Work Group. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol 2017; 130:e251. Reaffirmed 2019.</a></li><li><a class="nounderline abstract_t">Assaf A, el Tagy A, el Kady A, el Agezy H. Hysteroscopic removal of copper-containing intrauterine devices with missing tails during pregnancy. Adv Contracept 1988; 4:131.</a></li><li><a class="nounderline abstract_t">Lin JC, Chen YO, Lin BL, Valle RF. Outcome of removal of intrauterine devices with flexible hysteroscopy in early pregnancy. J Gynecol Surg 1993; 9:195.</a></li><li><a class="nounderline abstract_t">Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception 2007; 76:267.</a></li><li><a class="nounderline abstract_t">Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril 2012; 97:616.</a></li><li><a class="nounderline abstract_t">Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999; 31:64.</a></li><li><a class="nounderline abstract_t">Nilsson CG, Lahteenmaki PL, Luukkainen T, Robertson DN. Sustained intrauterine release of levonorgestrel over five years. Fertil Steril 1986; 45:805.</a></li><li><a class="nounderline abstract_t">Lähteenmäki P, Nilsson CG. Plasma concentrations of ethinylestradiol and D-norgestrel during two immediate postabortal oral contraceptive cycles. Contraception 1978; 17:9.</a></li><li><a class="nounderline abstract_t">Jensen JT. Contraceptive and therapeutic effects of the levonorgestrel intrauterine system: an overview. Obstet Gynecol Surv 2005; 60:604.</a></li><li><a class="nounderline abstract_t">Vickery Z, Madden T, Zhao Q, et al. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception 2013; 88:503.</a></li><li><a class="nounderline abstract_t">Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression. JAMA Psychiatry 2016; 73:1154.</a></li><li><a class="nounderline abstract_t">Higgins JA, Sanders JN, Palta M, Turok DK. Women's Sexual Function, Satisfaction, and Perceptions After Starting Long-Acting Reversible Contraceptives. Obstet Gynecol 2016; 128:1143.</a></li><li><a class="nounderline abstract_t">Boozalis A, Tutlam NT, Chrisman Robbins C, Peipert JF. Sexual Desire and Hormonal Contraception. Obstet Gynecol 2016; 127:563.</a></li><li><a class="nounderline abstract_t">Roura E, Travier N, Waterboer T, et al. The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoS One 2016; 11:e0147029.</a></li><li class="breakAll">World Health Organization. Medical eligibility criteria for contraceptive use. Fifth Edition. World Health Organization; Geneva, 2015.</li><li><a class="nounderline abstract_t">Kim YJ, Youm J, Kim JH, Jee BC. Actinomyces-like organisms in cervical smears: the association with intrauterine device and pelvic inflammatory diseases. Obstet Gynecol Sci 2014; 57:393.</a></li><li><a class="nounderline abstract_t">Persson E, Holmberg K. A longitudinal study of Actinomyces israelii in the female genital tract. Acta Obstet Gynecol Scand 1984; 63:207.</a></li><li><a class="nounderline abstract_t">Lippes J. Pelvic actinomycosis: a review and preliminary look at prevalence. Am J Obstet Gynecol 1999; 180:265.</a></li><li class="breakAll">Diouf, K, Harvard Medical School, 2018, personal communication.</li><li><a class="nounderline abstract_t">Roke CM. A comparative study of the ease of removal of intrauterine contraceptive devices. Contraception 1988; 37:555.</a></li><li><a class="nounderline abstract_t">Waldron K. Intrauterine devices: insertion and removal: practical procedures. Aust Fam Physician 1982; 11:40.</a></li><li><a class="nounderline abstract_t">Bounds W, Hutt S, Kubba A, et al. Randomised comparative study in 217 women of three disposable plastic IUCD thread retrievers. Br J Obstet Gynaecol 1992; 99:915.</a></li><li><a class="nounderline abstract_t">Tugrul S, Yavuzer B, Yildirim G, Kayahan A. The duration of use, causes of discontinuation, and problems during removal in women admitted for removal of IUD. Contraception 2005; 71:149.</a></li><li><a class="nounderline abstract_t">Prabhakaran S, Chuang A. In-office retrieval of intrauterine contraceptive devices with missing strings. Contraception 2011; 83:102.</a></li><li><a class="nounderline abstract_t">Marchi NM, Castro S, Hidalgo MM, et al. Management of missing strings in users of intrauterine contraceptives. Contraception 2012; 86:354.</a></li><li><a class="nounderline abstract_t">Verma U, Astudillo-Dávalos FE, Gerkowicz SA. Safe and cost-effective ultrasound guided removal of retained intrauterine device: our experience. Contraception 2015; 92:77.</a></li><li><a class="nounderline abstract_t">Swenson C, Royer PA, Turok DK, et al. Removal of the LNG IUD when strings are not visible: a case series. Contraception 2014; 90:288.</a></li><li><a class="nounderline abstract_t">Turok DK, Gurtcheff SE, Gibson K, et al. Operative management of intrauterine device complications: a case series report. Contraception 2010; 82:354.</a></li><li><a class="nounderline abstract_t">Wilson S, Tan G, Baylson M, Schreiber C. Controversies in family planning: how to manage a fractured IUD. Contraception 2013; 88:599.</a></li></ol></div><div id="topicVersionRevision">Topic 5422 Version 85.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34748746" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Society of Family Planning Committee statement on IUD nomenclature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22015868" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Malpositioned intrauterine contraceptive devices: risk factors, outcomes, and future pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24499755" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effects of age, parity, and device type on complications and discontinuation of intrauterine devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25198262" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Association of age and parity with intrauterine device expulsion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23168755" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25836384" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Positive testing for Neisseria gonorrhoeae and Chlamydia trachomatis and the risk of pelvic inflammatory disease in IUD users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1347812" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Intrauterine devices and pelvic inflammatory disease: An international perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21477680" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Contraceptive failure in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25601352" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25601352" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24201685" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27823942" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23635730" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Complications and continuation of intrauterine device use among commercially insured teenagers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26817571" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26116873" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Insertion characteristics of intrauterine devices in adolescents and young women: success, ancillary measures, and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22067773" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : IUD use in adolescent mothers: retention, failure and reasons for discontinuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27771475" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The safety of intrauterine devices among young women: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10640159" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9494767" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3311626" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effectiveness of IUDs: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3118580" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mechanism of action, safety and efficacy of intrauterine devices. Report of a WHO Scientific Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20464722" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Immediate post-partum insertion of intrauterine devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20556754" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Immediate postabortal insertion of intrauterine devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24769941" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of intrauterine device expulsion rates after aspiration abortion or interval insertion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35658995" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6152803" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Is lactation a risk factor of IUD- and sterilization-related uterine perforation? A hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12266198" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : IUD--related uterine perforation: an epidemiologic analysis of a rare event using an international dataset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2688380" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Insertional pain and other IUD insertion-related rare events for breastfeeding and non-breastfeeding women--a decade's experience in developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6823347" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk of uterine perforation among users of intrauterine devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27421765" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The safety of intrauterine devices in breastfeeding women: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35226086" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Association of the Timing of Postpartum Intrauterine Device Insertion and Breastfeeding With Risks of Intrauterine Device Expulsion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17018498" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Use of intrauterine device in the setting of uterus didelphys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26342448" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Levonorgestrel Intrauterine Device Placement in a Premenopausal Breast Cancer Patient with a Bicornuate Uterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20682142" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intrauterine device use among women with uterine fibroids: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2189670" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Do retroverted uteri adversely affect insertions and performance of IUDs?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12618260" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Uterine factors and risk of pregnancy in IUD users: a nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21272883" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Length of the endometrial cavity and intrauterine contraceptive device expulsion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24512656" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Dimensions of the endometrial cavity and intrauterine device expulsion or removal for displacement: a nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30095776" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Paracervical Block for Intrauterine Device Placement Among Nulliparous Women: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28885425" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Reducing Pain During Intrauterine Device Insertion: A Randomized Controlled Trial in Adolescents and Young Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29792756" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Uterine or paracervical lidocaine application for pain control during intrauterine contraceptive device insertion: a meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20876899" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The width of the uterine cavity is narrower in patients with an embedded intrauterine device (IUD) compared to a normally positioned IUD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26042815" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Sexually transmitted diseases treatment guidelines, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35793228" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Ultrasound-guided repositioning technique for partially expelled intrauterine device: descriptive feasibility study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14667326" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Analysis of risk factors associated with uterine perforation by intrauterine devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16472566" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Uterine perforation in women using a levonorgestrel-releasing intrauterine system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22763376" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Intrauterine contraception: incidence and factors associated with uterine perforation--a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/79760" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Anti-prostglandin therapy in prevention of side-effects of intrauterine contraceptive devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31226322" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Tamoxifen for the prevention of unscheduled bleeding in new users of the levonorgestrel 52-mg intrauterine system: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27824753" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Naproxen Sodium for Pain Control With Intrauterine Device Insertion: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26241253" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Ketorolac for Pain Control With Intrauterine Device Placement: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27823944" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect of cervical lidocaine-prilocaine cream on pain perception during copper T380A intrauterine device insertion among parous women: A randomized double-blind controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27500351" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Self-Administered Lidocaine Gel for Intrauterine Device Insertion in Nulliparous Women: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16413845" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11041414" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intrauterine device and upper-genital-tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9546505" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1899136" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27343750" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Safety of intrauterine devices among women with HIV: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27343750" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Safety of intrauterine devices among women with HIV: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23040135" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Retention of intrauterine devices in women who acquire pelvic inflammatory disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467319" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : U.S. Selected Practice Recommendations for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17531616" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : IUDs and colonization or infection with Actinomyces.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25046805" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26598302" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Therapeutic Options for Unscheduled Bleeding Associated with Long-Acting Reversible Contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30247074" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use: a randomised double-blind clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3516203" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Ibuprofen prevents IUCD-induced increases in menstrual blood loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17712656" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6336951" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28218963" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Women's willingness and ability to feel the strings of their intrauterine device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8922872" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11927115" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16284061" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19369294" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3677676" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The effect of acetylsalicylic acid on menstrual blood loss in women with IUDs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19565532" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Three-dimensional ultrasound detection of abnormally located intrauterine contraceptive devices which are a source of pelvic pain and abnormal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16448955" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The evaluation of 318 intrauterine pregnancy cases with an intrauterine device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416443" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Intrauterine device failure: relation to its location within the uterine cavity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Intrauterine location and expulsion of intrauterine device</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16307965" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Spontaneous upward movement of lowly placed T-shaped IUDs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : T-shaped IUDs accomodate to their position during the first three months after insertion</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27548557" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Committee Opinion No 672: Clinical Challenges of Long-Acting Reversible Contraceptive Methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36357958" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Demographic, Reproductive, and Medical Risk Factors for Intrauterine Device Expulsion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35395215" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Association between intrauterine device type and risk of perforation and device expulsion: results from the Association of Perforation and Expulsion of Intrauterine Device study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8747044" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Performance of copper intrauterine devices when inserted after an expulsion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16775156" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Risk factors for IUD failure: results of a large multicentre case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33189897" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Rates of Intrauterine Device Expulsion Among Adolescents and Young Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25101364" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Immediate postabortal insertion of intrauterine devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22018119" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Intrauterine contraceptive insertion postabortion: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33651995" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Relationship of parity and prior cesarean delivery to levonorgestrel 52 mg intrauterine system expulsion over 6 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1458889" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Risk factors for copper T IUD expulsion: an epidemiologic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23177264" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21651392" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Immediate versus delayed IUD insertion after uterine aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37330009" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pregnancy with retained intrauterine device: national-level assessment of characteristics and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8521711" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : IUD use and the risk of ectopic pregnancy: a meta-analysis of case-control studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8293847" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: A multicenter study. International Committee for Contraception Research (ICCR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3111785" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36943224" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Ectopic Pregnancy Risk in Users of Levonorgestrel-Releasing Intrauterine Systems With 52, 19.5, and 13.5 mg of Hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21691183" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : ACOG Practice Bulletin No. 121: Long-acting reversible contraception: Implants and intrauterine devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19650756" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The prognosis of pregnancy conceived despite the presence of an intrauterine device (IUD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pregnancy outcome in women with an intrauterine contraceptive device</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4820906" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The in situ IUD and pregnancy outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/602718" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Outcome of pregnancy in the presence of intrauterine device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1033668" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Management and outcome of pregnancies associated with the Copper T intrauterine contraceptive device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29064972" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3213670" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Hysteroscopic removal of copper-containing intrauterine devices with missing tails during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10146639" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Outcome of removal of intrauterine devices with flexible hysteroscopy in early pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17900435" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Contraceptive discontinuation attributed to method dissatisfaction in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22222193" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10224544" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3086130" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Sustained intrauterine release of levonorgestrel over five years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/627151" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Plasma concentrations of ethinylestradiol and D-norgestrel during two immediate postabortal oral contraceptive cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16121115" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Contraceptive and therapeutic effects of the levonorgestrel intrauterine system: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23582238" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Weight change at 12 months in users of three progestin-only contraceptive methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27680324" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Association of Hormonal Contraception With Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27741195" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Women's Sexual Function, Satisfaction, and Perceptions After Starting Long-Acting Reversible Contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26855094" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Sexual Desire and Hormonal Contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26808155" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26808155" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25264530" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Actinomyces-like organisms in cervical smears: the association with intrauterine device and pelvic inflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6375245" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : A longitudinal study of Actinomyces israelii in the female genital tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9988785" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Pelvic actinomycosis: a review and preliminary look at prevalence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9988785" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Pelvic actinomycosis: a review and preliminary look at prevalence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3396356" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : A comparative study of the ease of removal of intrauterine contraceptive devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7065991" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Intrauterine devices: insertion and removal: practical procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1450143" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Randomised comparative study in 217 women of three disposable plastic IUCD thread retrievers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15707566" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : The duration of use, causes of discontinuation, and problems during removal in women admitted for removal of IUD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21237334" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : In-office retrieval of intrauterine contraceptive devices with missing strings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22459233" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Management of missing strings in users of intrauterine contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25708503" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Safe and cost-effective ultrasound guided removal of retained intrauterine device: our experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24835830" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Removal of the LNG IUD when strings are not visible: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20851229" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Operative management of intrauterine device complications: a case series report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24028753" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Controversies in family planning: how to manage a fractured IUD.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
